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Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoid malignancy. About
30% of DLBCL cases respond poorly to initial treatment and eventually relapse. For these patients,
the current treatment regimen is quite limited, and the prognosis is poor. Gene mutations and
genetic alterations play an important role in lymphomagenesis. However, the genetic alterations or
gene mutations underlying the disease resistance/relapse in DLBCL are still unknown. The clonal
evolution during the process of disease progression is elusive as well. Our goal is to study the
genetic alterations in DLBCL, particularly paired diagnostic and relapsed/refractory DLBCL, to
better understand the mutation landscape of relapsed/refractory DLBCL and identify potential
novel targets for effective therapy.
We performed whole-exome sequencing (WES) on 16 pairs of diagnostic and
relapsed/refractory DLBCL samples. In addition, the WES data of seven diagnostic and
relapsed/refractory pairs were downloaded, as well as another 30 relapsed cases, each with a paired
germline. In total, 23 pairs were analyzed all together to discover the mutation landscape for
relapsed/refractory DLBCL. These results were validated in the 30 relapsed cases when needed. We
classified our DLBCL cases into MCD, BN2, N1, and EZB subtypes according to the recently
developed classification based on genomic abnormalities. The MCD subgroup was found to be
enriched in our relapsed/refractory cohort, suggesting the MCD subgroup was prone to relapse.
Consistently, MYD88 mutations, a hallmark for the MCD subgroup, were enriched in our
relapsed/refractory cohort as well. Moreover, two different evolution patterns (Pattern 1 and 2)
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were revealed. Pattern 1 cases carried more original mutations to relapse, whereas Pattern 2 cases
had a considerable number of novel variants only present in the relapsed/refractory sample.
Interestingly, Pattern 2 was correlated to worse prognoses, such as shorter relapse-free survival.
With further validation, these data can assist in precise clinical decisions; for example, patients
with Pattern 2 may have worse prognoses predictions and thus be subjected to more intense
therapies. Additionally, we discovered that the canonical NF-κB signaling pathway mutations
probably play a critical role in DLBCL relapse. The novel potential target genes in the NF-κB
pathway included SHARPIN, PTPN14, and TMSB4X. Finally, we identified a rare fusion
between MYC and its non-IG partner Activation-induced Cytidine Deaminase (AICDA) in our
relapsed/refractory cohort by RNA-sequencing. Notably, this de novo fusion significantly evolved
after treatment, indicating it was resistant to the R-CHOP (rituximab, cyclophosphamide,
doxorubicin hydrochloride, vincristine, and prednisolone) immunochemotherapy and expanded
over the course of treatment. These results suggest the AICDA-MYC fusion is a potential prognostic
marker and may mediate DLBCL relapse.
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Chapter 1: Introduction
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B cell development
The immune system is a complex network comprising various immune organs, cells, and
cytokines to defend our body against invaders, which include viruses and bacteria. Immune cells
are produced and derived from hematopoietic stem cells in the primary lymphoid organs such as
the thymus and bone marrow, as well as secondary lymphatic tissues, which include the spleen and
lymph nodes. The immune defense functions under delicate regulations and is composed of the
innate and adaptive immune systems. The major immune cells in the innate immune system contain
phagocytes, mast cells, eosinophils, basophils, and natural killer cells, whereas the key immune
cells in the adaptive immune system are lymphocytes, such as B cells and T cells. (Chaplin 2010,
Nicholson 2016)
The immune cells undergo distinct differentiation pathways. Our study has been focused
on the B-cell lymphomas. The ultimate purpose of B cell development is to generate B-cellreceptors (BCRs) with a large variety but no self-reactivity. This purpose is achieved by three major
sequential steps, including generation of various BCRs, elimination of self-reactive BCRs and
promotion of BCR affinities by selection. The structure of BCR and the crucial events occurred in
B cell development will be discussed in detail in the following paragraphs. Each stage of B cell
development is fine regulated. Dysregulation of different stages results in distinct types of
lymphomas.
Structure of BCR
BCRs are membrane bound immunoglobulins, which not only have the structure of
secreted antibodies but also have additional transmembrane and cytoplasmic domains (Figure 1.1).
The BCR consists of a heavy chain and a light chain, each including a constant region and a variable
region. The constant region is relatively conserved and inherited, whereas the variable region
exhibits a large variety of sequences for recognizing distinct pathogens. The variable region and
part of the constant region make up the antigen binding structure. Additionally, the membrane and
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cytoplasmic domains of BCR are extremely short. Thus, accessory protein dimers consisting of Igα
and Igβ are essential in the signal transduction, connecting the BCR to the tyrosine phosphorylation
pathways in the cell (Friess, Pluhackova and Böckmann 2018). Igα and Igβ are also known as
CD79A and CD79B in B cell, whose mutations play vital roles in B-cell lymphomas (Matsuuchi
and Gold 2001).
Generation of various BCRs
In BCR, each heavy chain variable region is encoded by three gene segments on
chromosome 14, including a variable (V), a joining (J), and a diversity (D) segment, whereas each
light chain variable region is encoded by a V segment and a J segment, located on chromosome 2
and 22 (Onozawa and Aplan 2012). The generation of the vast repertoire of BCR was mainly
accomplished by somatic recombination, which is the rearrangement of gene segments encoding
heavy and light chains. In bone marrow, pro-B cells are derived from common lymphoid
progenitors. The produce of heavy chain variable region is achieved by D-J recombination firstly
in the early pro-B cells, and then V-DJ recombination in the late pro-B cells. Notably, the
recombination occurs on one chromosome first. Once succeeded, it would not proceed on the
second chromosome, which is called allelic exclusion (ten Boekel, Melchers and Rolink 1998).
Due to allelic exclusion, one B cell only has one set of heavy chain VDJ, leading to one unique
specificity (Pernis et al. 1965). Thus, sequencing the VDJ sequence is an effective way to identify
different clones within the same tumor (Jiang et al. 2014). Alternatively, if the recombination fails
on the first chromosome, the recombination on the second chromosome starts, until running out of
genetic materials. In the somatic recombination, approximately 50% of the cells die because of not
successfully rearranging V, D, and J segments.
Somatic recombination is initiated by recombination activating gene 1 (RAG1) and RAG2
proteins, which cut the recombination signal sequences adjacent to each V/D/J segments (Schatz
and Ji 2011, Schatz and Swanson 2011, Helmink and Sleckman 2012). The recombination signal
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sequences are conserved sequences, separated by 12 or 23 spacer sequences. Recombination can
only get accomplished between signal sequences with different length of spacer sequences (12-23,
or 23-12), which is also known as “the 12/23 rule”. However, because the DNA must be cut for
millions of times over the lifetime, this process also creates errors leading to B-cell
lymphomagenesis (Roth 2014, Papaemmanuil et al. 2014). For example, one of the well-known
chromosome translocation contributing to B-cell lymphomas t(14;18) is believed to rise from
mistakes in somatic recombination (Tsujimoto et al. 1985).
Next, in the large pre-B cell stage, the heavy chain variable region encoded by the newly
rearranged VDJ is linked with the µ constant region to form a complete heavy chain. Then the
heavy chain partners with the surrogate light chain (VpreB and λ5) to validate its capability of
pairing with light chains (Keyna et al. 1995, Kudo, Sakaguchi and Melchers 1987). The temporary
combination between the heavy chain and the surrogate light chain is also known as pre-B receptor.
It is noteworthy that this test occurs in the endosome within large pre-B cells.
Once the pre-B receptors are demonstrated to be functional, the specific large pre-B cell would
proliferate massively and enter the small pre-B cell stage, during which the light chain variable
region is rearranged by V-J recombination. Light chain is resigned as a κ chain by default. The VJ recombination occurs on the κ segments of the first chromsome. If the recombination fails, it will
try on the κ sements of the second chromsome, the λ sements of the first chromsome, and then the
λ sements of the second chromsome, sequentialy, until running out of genetic materials.
Alternatively, if the first try on the κ segments of the first chromsome succeeds, the B cells proceed
to auto-reactivity selection. The ratio of κ to λ is an important prognostic marker in multiple
myeloma (Rajkumar et al. 2005). After the accomplishment of somatic recombination, immature
BCRs with µ constant regions (IgM) are generated.
The achievement of the large variety of BCR is based on two major layers. Firstly, VDJ
recombination lead to distinct VDJ sequences. Secondly, once the VDJ recombination is
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demonstrated to be functional, the pre-B cells proliferate massively. Later, each VDJ clone bind to
many different light chains to amplify the BCR variety.
Elimination of sef-reactive BCRs
Before B cells are relased into circulation from the bone marrow, they will be tested for
their ability to bind to self-antigens (Nemazee and Buerki 1989), failure of which can lead to
autoimmune diseases. Self-antigen molecules are mainly provided by bone marrow stromal cells,
hematopoetic cells, and molecules circulating in blood plasma. Elimination or inactivation of B
cells depends on the strength with which the BCR binds to self-antigens in the bone marrow. Most
of the self-antigen molecules are multivalent. If the BCR binds to multivalent self-antigens
strongly, the B cells will go through apoptosis, which is also known as clonal deletion; if the
interactions between the BCR and multivalent self-antigens are absent or weak, the B cells will be
relased with both IgM and IgD types after alternative splicing, which is the rearrangement of heavy
chain constant regions on the RNA level to form distinct types of immunoglobulins; if the BCR
binds to the autoantigen moderately, the κ chain will be replaced by a λ chain and resubmitted to
check for the self-reactivity. This process is also known as receptor editing (Casellas et al. 2001).
Additionally, some monovalent self-antigens are also present in the bone marrow, which bind to
self-reactive B cells and turned their BCR unresponsive. These B cells will not die instantlly.
Instead, they enter the peripheal circulation and undergo apoptosis in a couple days. The process is
known as anergy.
Promotion of BCR affinities by selection
After released from the bone marrow, immature B cells migrate to lymph nodes, where
they are activated by T helper cells or antigens and then translocated to the germinal center as
centroblasts. In the dark zone of germinal center, somatic hypermutation accumulates with the
regulation of Activation-induced cytidine deaminase (AICDA) (Muramatsu et al. 2000, Revy et al.
2000). AICDA generates mutagenic positions by converting cytosine to uracil within the
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immunoglobulin loci. After the somatic hypermutation, the centroblasts with diverse antigen
affinities migrate to the light zone and undergo selection as centrocytes. The centrocytes with high
antigen affinities proceed with class switching to produce Ig G/A/M/E/D, while these with low
antigen affinities are arrested and, eventually, die. In the class switching, AICDA plays a vital role
as well (Lieber, Yu and Raghavan 2006).
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is one of the most common aggressive B-cell
lymphomas, comprising approximately 30% of newly diagnosed non-Hodgkin lymphoma (NHL).
It predominantly occurs in male (55%), especially males elder than 60 years old (Siegel, Miller and
Jemal 2019). There are two major biologically distinct molecular subtypes of DLBCL: germinal
center B-cell (GCB) and activated B-cell (ABC) subtypes (Alizadeh et al. 2000). Besides, there is
a third subgroup, the unclassified DLBCL. ABC and unclassified subtypes are also known as the
non-GCB subgroup. Different subgroups are believed to arise from different stages of lymphoid
differentiation. The GCB subtype DLBCL arises from the centroblasts or centrocytes, whereas the
non-GCB subtype DLBCL arises from the plasmablastic cells.
The DLBCL patients typically present with a rapidly enlarging symptomatic mass, mostly
in the neck or abdomen. Advanced stage (stage III or IV), extranodal involvement, and systemic
‘B’ symptoms, such as fever, weight loss, drenching night sweats, are common. More than 50% of
the DLBCL patients have elevated level of the serum lactate dehydrogenase (LDH). DLBCL
pathology is characterized by large, transformed B cells with prominent nucleoli and basophilic
cytoplasm, a diffuse growth pattern and a high (> 40%) proliferation fraction. (Tilly et al. 2015)
The current standard treatment for DLBCL is the R-CHOP (rituximab, cyclophosphamide,
doxorubicin hydrochloride, vincristine, and prednisolone) immunochemotherapy. The use of the
recombinant anti-CD20 antibody rituximab has dramatically improved the prognosis of B-cell
lymphoma patients (Silverman and Weisman 2003, Maloney et al. 1994, McLaughlin et al. 1998,
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Hainsworth et al. 2000). Rituximab is a chimeric monoclonal antibody with murine anti-CD20
variable regions and human IgG κ type constant regions, which targets the CD20 antigen on the
surface of malignant as well as normal B cells and leads to lymphopenia (Wang et al. 2006). The
mechanisms of Rituximab are not fully elucidated. Some studies demonstrated that the possible
mechanisms include complement-dependent cytotoxicity, complement-dependent cellular
cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis etc. (Pedersen et
al. 2002, Manches et al. 2003, Bowles et al. 2006), (Weiner 2010, Shan, Ledbetter and Press 2000).
The prognosis of DLBCL patients has been improved in the immunotherapy era. Still,
about 30% of these patients are refractory or relapse after the initial standard chemotherapy. For
these patients, survival is poor: only 10% of them achieve 5-yr-progression-free survival (Friedberg
2011). To date, there has been little understanding of the mechanisms for the resistance/recurrence.
The issue has been studied more with the development of the Next-generation sequencing
(NGS) technique. NGS is a powerful method for profiling gene mutations by massive parallel
sequencing, among which whole-exome sequencing (WES) and Targeted Sequencing are two
wildly used approaches. WES is a cost-effective alternative to whole-genome sequencing (WGS)
by solely focusing on the exome, which represents less than 2% of the genetic codes but contains
about 90% of known disease-related variants, whereas Targeted Sequencing is a rapid way to detect
variants in selected sets of genes or genomic regions. Compared with WES, Targeted Sequencing
is more economic. However, as a trade-off, Targeted Sequencing has a limited targeting scope.
Most studies in the field of DLBCL NGS were sampled randomly in the diagnostic and the
relapsed/refractory samples. Until more recently, literature has emerged that offers findings of gene
evolution between the paired diagnostic and relapsed/refractory samples from the same patient.
These results helped to develop a better understanding of the resistance mechanisms. Also, DLBCL
is a heterogeneous disease, and these studies shed light on precise medicines for different
individuals. However, these sequencing studies have only been carried out either in a very small
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number of diagnostic and relapsed/refractory pairs or solely on a limited number of target genes.
Here, we reviewed recent sequencing studies in DLBCL diagnostic and relapsed/refractory pairs.
NGS studies with paired diagnostic and relapsed samples
We searched MEDLINE with search strategy: (dlbcl [Title/Abstract]) AND relapse
[Title/Abstract] AND sequencing [Title/Abstract]. We identified 25 studies in total, among which
six studies included data on paired diagnostic and relapsed DLBCL samples (Jiang et al. 2014,
Morin et al. 2016, Melchardt et al. 2016, Greenawalt et al. 2017, Juskevicius et al. 2016, Nijland et
al. 2018). These representative papers are shown in Table 1.1. All six studies were published in the
recent 5 years. Among these studies, three employed WES and the other three made use of Targeted
Sequencing with customized panels, each including 68, 104, and 29 genes in their panel.
In these six studies, eleven genes were covered by all three target-panels as well as by the
WES. The genes are B2M, BTG1, CD79B, CREBBP, EZH2, FOXO1, MYC, MYD88, PIM1, SGK1,
and STAT6. The mutation frequencies of the eleven genes in both diagnostic and relapsed samples
in the six studies, as well as data from published cohorts, were summarized in Table 1.2. Their
mutation frequencies reported by COSMIC (https://cancer.sanger.ac.uk/cosmic) were also listed as
a reference. Firstly, the mutation frequencies in each study were not exactly consistent with each
other or with COSMIC data. One possible reason is the limited sample size, and another possible
explanation is that these patients were all eventually relapsed, making them a special pool from the
total patients. Secondly, the mutation evolution trend of each gene in different studies was not
persistent either. For example, the mutation frequency of CD79B decreased in relapsed samples
compared with diagnostic samples in three studies, but increased in the study by Melchardt T, et
al. The inconsistency was in almost all the eleven genes, except for MYC and MYD88, whose
mutation frequency increased or maintained in all four studies with available data. Overall, because
of the heterogeneity of each mutation, the gene mutation frequency only provided limited
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information, failing to offer more dynamic evolution details. Thus, studies in larger cohorts with
paired diagnostic and relapsed DLBCL samples are needed.
Hot-spot mutations and pathways in DLBCL
Most of the targetable mutations identified by sequencing are in a few classic pathogenic
pathways in DLBCL, including the NF-κB, epigenetic, and other pathways such as the JAK-STAT
pathway (Figure 1.1). Here, we summarize the common hot-spot mutations revealed in NGS and
their molecular mechanisms.
NF-κB pathway
MYD88 is an adaptor protein between activated Toll-Like-Receptor (TLR) dimers and IL1
receptor-associated kinase 4 (IRAK4) (Kraan et al. 2013). IRAK1 and IRAK2 bind to IRAK4
afterward and form Myddosome. Phosphorylated IRAK1 and IRAK2 recruit ubiquitin ligase
TARF6, which promotes the activity of ITA1. IKKβ is then activated by ITA1 and phosphorylates
Iκβ. In normal cells, NF-κB is sequenced by Iκβ in the cytoplasm. Phosphorylated Iκβ disassociates
with NF-κB, exposing NF-κB Nuclear-Localization-Signal (NLS). Consequently, NF-κB is
translocated to the nucleus, binds to response elements on DNA, and thereby controls gene
transcription, resulting in a change in cell function. In summary, MYD88 upregulates the NF-κB
pathway. Additionally, MYD88 enhances the JAK-STAT pathway activity through ITA1 as well.
MYD88 L265P (also known as L273P) was a hot-spot mutation in both diagnostic and
relapsed patients (Yu et al. 2018). Its high incidence in relapsed samples indicated its possible
resistance to R-CHOP therapy. This mutation was reported to be independently associated with
poor outcomes in DLBCL patients, but previous studies of MYD88 L265P have not dealt with its
role in resistance (Fernández-Rodríguez et al. 2014). MYD88 L265P was known as a gain-offunction-mutation. The dysregulation of the NF-κB pathway plays a vital role in the ABC DLBCL.
Thus, it is not surprising that MYD88 L265P was affiliated with the ABC DLBCL, but rarely in the
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GCB subtype. This mutation is in the hydrophobic core of the Toll/interleukin-1 receptor domain
(TIR), which is responsible for binding TLR. The mutation’s possible mechanism is that the
proline, which disturbs protein structure the most especially in beta-sheet, dramatically changes the
three-dimensional-structure of TIR and enhances its binding to TLR. Another hot-spot MYD88
mutation S219C identified resides in TIR as well and has a similar mechanism. It has previously
been reported that MYD88 L265P drives nearly 30% of the ABC DLBCL. Interestingly, in 24% of
the ABC DLBCL, A20 loss-of-function accompanies MYD88 gain-of-function, indicating second
hits are essential for MYD88 function as an oncogene. Overall, patients in the ABC subgroup
respond poorly to the current R-CHOP chemotherapy and comprise the main part of
resistant/relapsed patients. Taken together, recent sequencing studies confirm that MYD88
mutations, especially L265P, are significant causes for treatment resistance/relapse in DLBCL
patients. However, more paired sequencing data are needed for studying MYD88 evolution patterns.
CD79B mutations were reported to be in about 30% of DLBCL patients with MYD88
mutations (Kraan et al. 2013, Nakamura et al. 2016). Much like MYD88, CD79B regulates the NFκB pathway as well. CD79B proteins, together with CD79A, are cytoplasmic components of BCR
for transducing signals, specifically by their immunoreceptor tyrosine-based activation motif
(ITAM). Upon antigen binding, the tyrosine residues in ITAMs of both CD79A and CD79B are
phosphorylated by SRC-family kinases (SFK, e.g., LYN, FYN, FGR, and BLK). Consequently,
spleen tyrosine kinases (SYK) are recruited and activated, which impels the downstream signaling
cascades, including phosphorylation and activation of Bruton tyrosine kinase (BTK) and
phospholipase Cγ2 (PLCγ2). The activated BTK, BLNK, and PLCγ2 complex catalyzes
phosphatidylinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate
(IP3). The production of IP3 leads to the opening of calcium channels and elevates the intracellular
calcium level, which activates protein kinase C β (PKCβ) with DAG jointly. The triggered PKCβ
phosphorylates and activates CARD11, which recruits BCL10 and MALT1. This complex
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phosphorylates IKKβ through TAB2. Then, IKKβ phosphorylates Iκβ, leading to the release of NFκB. As a result, NF-κB is transported into the nucleus and acts as a transcription factor. CD79B
mutations are in the ABC, but not the GCB subgroup. Y196 is a well-known mutation hot spot
located in the ITAM of CD79B. Y196X mutations lead to the chronic BCR activation, possibly
through repressing SFK’s negative feedback and therefore overexpressing BCR on the cell
membrane.
Epigenetic pathway
EZH2 is a histone methyltransferase and forms Polycomb repressive complex group 2
(PRC2) together with SUZ12, and EED. This complex promotes methylation of lysine 27 residue
of histone 3 (H3K27). The methylation level of H3K27 is consistent with the gene repression level.
In the normal germinal center, EZH2 is activated to maintain germinal center reaction. To exit B
cells from the germinal center, a specific bivalent chromatin domain needs to be formed under the
regulation of EZH2. Thereby, B cells with EZH2 mutations are trapped in germinal center
hyperplasia. In these cells, EZH2 activation in cooperation with BCL2 overexpression or p53 loss
accelerates lymphoma progression. (Béguelin et al. 2013, Béguelin et al. 2016, Béguelin et al.
2017)
EZH2 mutations primarily happen at Y646 in the STEM domain and they are usually gainof-function (Souroullas et al. 2016). Y646X mutations increase the H3K27-trimethylation because
substitutions with smaller amino acids (asparagine, serine, histidine, phenylalanine, and cysteine,
etc.) at Y646 creates a bigger catalytic pocket for H3K27 to freely rotate and form bonds.
Interestingly, due to this conformational change, the EZH2Y646X, not like EZH2wild-type, cannot
initiate the formation of H3K27 mono-methylation, but only promotes mono- to bi-, and bi- to trimethylation. Thus, the activity of EZH2Y646X partially depends on the EZH2wild-type. As a result, B
cells with heterogenous EZH2 Y646 mutations are prone to develop lymphoma with a second-hit
signal, such as BCL2 dysregulation. Because of this mechanism, EZH2 Y646 mutations were found
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in up to 21% of the GCB, but not in the ABC DLBCL patients. Recently, investigators have
examined the effects of EZH2 inhibitors in the GCB DLBCL cell lines. As expected, cell lines with
EZH2 mutations were more sensitive than the wild type. Some studies reported EZH2 inhibitors
effectively repressed proliferation in both EZH2Y646X and EZH2wild-type GCB cell lines when
combined with other drugs, including the glucocorticoid receptor agonist. However, the combined
effects and mechanisms between EZH2 inhibitors and traditional chemo-drugs or target therapies
have not been well-investigated. A couple of EZH2 small-molecule inhibitors, tazemetostat
(EPZ6438) and DS-3201b for example, are currently being evaluated in phase I/II clinical trials for
relapsed or refractory DLBCL (Knutson et al. 2014, Lue and Amengual 2018, McCabe et al. 2012).
CREBBP is a member of the histone acetyltransferases (HAT) family. It catalyzes posttranscriptional acetylation of lysine residues and thereby alters chromatin structures and
transcription factor activities. It plays a vital role in the balance between BCL6 and p53 in the
germinal center, where activated p53 leads to apoptosis while BCL6 promotes cells’ tolerance to
DNA breaks, to facilitate somatic hypermutations and class switch recombination. In this process,
CREBBP hinders onco-protein BCL6 and activates tumor-suppressor p53 both by acetylations.
Thus, CREBBP mutations, mainly by loss-of-function, contribute to lymphomagenesis by
increasing BCL6 and decreasing p53 activities. The CREBBP mutations are mainly in the GCB
subtype. The in-frame deletion at S1680 was highly recurrent, which possibly causes the
elimination or truncation of the HAT domain. This alteration was identified in 6 relapsed cases in
multiple sequencing studies, indicating its possible contribution to DLBCL relapse (Andersen et
al. 2012).
Other pathways
The JAK/STAT pathway plays a predominant role in IL-4/IL-13 and virus-mediated
signaling pathways (Springuel, Renauld and Knoops 2015, Villarino, Kanno and O'Shea 2017,
Yildiz et al. 2015). Before cytokine engagement, Janus kinase family, including JAK1, JAK2,
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JAK3, and TYK2, is initially docked at the intracellular of BCR. BCR oligomerizes at cytokine
binding and transactivates JAK, which then phosphorylates the tyrosine residues on the BCR
cytoplasmic part. Next, STAT is recruited to these phosphorylated tyrosine residues and put in
spatial proximity with JAK, leading to JAK phosphorylating STAT tyrosines. Phosphorylated
STAT homo- or heterodizes, transfers into the nucleus and ultimately modifies gene transcription.
The hot-spot mutation we are going to discuss is STAT6 D419G. Unlike MYD88 L265P or EZH2
Y646X, STAT6 D419G had been rarely studied in DLBCL. It was reported as a polymorphism in
online datasets. However, Morin RD, et al. considered it as a somatic mutation in
relapsed/refractory DLBCL because the variant allele was less than 1% in the paired germline
(Morin et al. 2016). They observed that the phospho-STAT6 level as well as STAT6 nucleus
localization were linked to STAT6 D419 mutations. Moreover, reported downstream targets
including SOCS1 were increased in the mutant cell lines. In summary, their results indicated STAT6
mutations, like in Follicular Lymphoma, gained functions possibly through activating the
JAK/STAT pathway. Moreover, STAT6 D419 recurred in the relapsed samples and exhibited a
clonal expansion in their cohort. This result was confirmed by Greenawalt DM, et al. as well.
Residue D419 is located on the protein-DNA interface of STAT6. The substitution of D by G
enhances the binding between STAT6 and DNA, therefore improving the residency of STAT6 in
the nucleus. Studies demonstrated that STAT6 D419 mutations were gain-of-function and promoted
the responsiveness to IL-4 in lymphoma cell lines.
Last but not least, another recurrent mutation identified by the sequencing studies in
DLBCL is PIM1 S188X. PIM1 is an isoform of proviral insertion in the murine leukemia virus
(PIM) family, which consists of PIM1, PIM2, and PIM3 (Xiang et al. 2018, Narlik-Grassow,
Blanco-Aparicio and Carnero 2014). These three members are highly homologous with conserved
amino acid sequences, but with different tissue distributions. PIM1 is highly expressed in
hematopoietic and lymphoid tissues. PIM1 is mainly regulated by the JAK/STAT pathway and
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functions as an oncogene through activating downstream the NF-κB pathway in DLBCL. Studies
showed PIM1 phosphorylated RelA/p65 at Ser276, thereby preventing the ubiquitination by
SOCS1 at this location and protein degradation (Nihira et al. 2010). PIM1 mutations were identified
in 48% of the DLBCL, mainly in the ABC subgroup. Consistent with their recurrence in the
relapsed DLBCL patients, PIM1 was reported to be correlated with progression and poor outcomes
in DLBCL (Brault et al. 2012). Unlike other kinases, PIM1 is constitutively active, thus, merely
regulated by its protein level. The S188X mutations have been barely studied and their mechanism
is unknown. These mutations stabilize PIM1 and promote its protein level. However, the S188X
mutations were only identified by Greenawalt DM, et al. The S188X mutations and their functions
required more conformation.
Meanwhile, mutations in other pathways such as TP53, PI3K-AKT-mTOR, and RAS
pathways were identified in DLBCL by NGS, which are not discussed in detail here.
Mutational evolution
The instability and heterogeneity of DLBCL cells provide the ground for evolution. The
mutation evolutional patterns and their mechanisms in DLBCL has been subject to considerable
discussion. The mutational evolution can be due to “pre-existing heterogeneity”, in which the
malignant clone is initially minor and then expand during treatment, resulting in relapse. In this
case, the primary variant allele frequency (VAF) is relatively low but the relapsed VAF is higher.
Other clones sensitive to chemotherapy are killed. Alternatively, the mutational evolution can be a
result of “ongoing genetic instability” during treatment. In this case, the resistant clones are induced
under the chemotherapy stress. The primary VAF might be zero and the relapsed VAF is high. This
kind of lymphoma usually holds more diversities compared to the first pattern. Notably, the two
kinds of events can both be ongoing in the same tumor. Moreover, it can either be a deterministic
process depending on the resistance of a certain clone, or a stochastic process, during which one
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out of several resistant clones expands by random and further promotes its survival by positive
feedback.
Overview of the chapters
In the previous paragraphs, we summarized the most highly recurrent hot-spot mutations
in both diagnostic and relapsed DLBCL samples, including MYD88 L265P, CD79B Y196X, EZH2
Y646X, STAT6 D419G, CREBBP S1680del, and PIM1 S188X. However, the major limitation of
the current data is that the sample size of each study is extremely small. It is hard to draw any
reliable conclusions on their evolutional events and patterns. Therefore, more sequencings on
paired diagnostic and relapsed/refractory samples with a larger sample size are needed. According
to our knowledge, this study includes the largest number of matched diagnostic and relapsed
DLBCL pairs.
The rest of this dissertation is organized as follows. In Chapter 2, we described our samples
and compared the mutation frequencies of well-known oncogenes between our data and published
data. The MYD88 mutations were revealed to be more enriched in our data. Additionally, we
applied the newly developed genetic subtype classification in the relapsed/refractory DLBCL cases
for the first time and found the MCD subgroup was more enriched in our relapsed/refractory
DLBCL cases. Moreover, we described the genome landscape including hot-spot mutations and
their evolution trends. For example, MYD88 L265 was identified to be highly recurrent and
malignant, with significant evolutions in most case pairs. In Chapter 3, we explored the evolutional
patterns in the diagnostic and relapsed/refractory pairs and correlated the patterns with clinical
characteristics. In this part, mainly two patterns (Pattern 1 and 2) were identified and Pattern 2 was
significantly correlated with a shorter relapse-free survival. In Chapter 4, we further dug in the
pathway we were most interested in: the NF-κB pathway. We proposed three potential genes within
the NF-κB pathway for future studies. In Chapter 5, we specifically studied a resistant MYC-nonIG fusion, which was identified in one of our diagnostic and relapsed/refractory case pairs. We
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validated the fusion with RT-PCR followed by Sanger sequencing as well as FISH studies. The
MYC and Ki-67 expression levels were detected to be elevated by Immunohistochemistry (IHC).
Additionally, a TMA screening was conduct using the FISH probes to address the recurrence of the
MYC-non-IG fusion. In Chapter 6, we summarized the major conclusions and discussed future
directions. Chapter 7 and Chapter 8 are materials and methods section and bibliography section,
respectively.
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Figures
Figure 1.1 BCR structure
BCR has the same structure with immunoglobulin. It has two light and two heavy chains, each
consisting of one variable region and one constant region. The heavy chain constant region includes
three segments: CH1, CH2, and CH3. The disulfide bonds bridge the light and heavy chains. Besides,
the VL, CL, VH, and CH1 compose the antigen-biding fragment, whereas the CH2 and CH3 form the
C-terminal fragment. Additionally, BCR consists of transmembrane and cytoplasmic domains.
However, the cytoplasmic domains are extremely short, which need the assistance of signal
transduction region. The signal transduction region is a heterodimer, comprising an Igα and an Igβ
stabilized by disulfide bonds. In B cells, Igα and Igβ are also known as CD79A and CD79B, which
are among top frequently mutated oncogenes in B-cell lymphomas.
VL denotes variable regions of light chains. CL denotes constant regions of light chains. VH denotes
variable regions of heavy chains. CH denotes constant regions of heavy chains. Fab denotes antigenbinding fragments and Fc denotes C-terminal fragments. Ag denotes antigen.
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Figure 1.2 B cell development
B cells are produced in the bone marrow and mature in the secondary lymphatic tissues, such as
lymph nodes. As a key component of the adoptive immune system, B cells are responsible for the
production of antibodies with various specificities. To achieve the purpose, appropriate BCRs need
to be created during the development of B cell. The major steps include generation of BCR with a
wide variety, elimination of self-reactive BCR, and selection of BCR affinity.
During the initial generation of BCR, somatic recombination plays vital role, which is the shuffle
and rearrangement of BCR heavy/light chain loci segments. Specifically, these segments include
V and J segments for light chains and V, J, and D segments for heavy chains. After derived from
the common lymphoid stem cell, Pro-B cells undergo D-J recombination and V-DJ recombination
sequentially in the early and late stages. Next, in large Pre-B cells the primary heavy chains are
produced with variable regions encoded by the newly rearranged VDJ loci, and constant regions
encoded as the µ type by default. These heavy chains partner with surrogate light chains, which
consists of VpreB and λ5, to form pre-B cell receptors. Once the BCR heavy chains are confirmed
to be functional, the specific pre-B cell will proliferate massively and enter the small pre-B cell
stage, in which V-J recombination occur on light chain loci.
Following generation of various BCR, the auto-reactivity will be tested. Depended on the binding
strength between BCR and auto-antigens, the possible results include B cell release, apoptosis,
receptor editing, or anergy. After the auto-antigen selection, both IgM and IgD would be expressed
on the surface and B cells migrate to secondary lymphatic tissues such as lymph nodes, where they
are activated and their BCR affinity are promoted by somatic hypermutation as well as selection.
Eventually, B cells express different types of antibodies (Ig G/A/M/E/D) and help defend various
pathogens.
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Figure 1.3 Classic pathogenic pathways in DLBCL
The NF-κB, JAK-STAT, and epigenetic pathways are the three critical pathways where most gene
mutations are identified in DLBCL by NGS. Additionally, other pathways including TP53, PI3KAKT-mTOR, and RAS pathways play vital roles in DLBCL as well.

- 20 -

Tables
Table 1.1 Summary of published NGS studies consisting of paired diagnostic and relapsed
DLBCL samples
Authors

Year

Diagnostic and Relapsed Pairs #

Methods

Nijland M, et al.

2018

6

Whole-exome sequencing

Greenawalt DM, et al.

2017

8

Whole-exome-sequencing

Juskevicius D, et al.

2016

20

Melchardt T, et al.

2016

5

Morin RD, et al.

2016

12

Jiang Y, et al.

2014

7
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Targeted Sequencing
(68-gene-panel)
Targeted Sequencing
(104-gene-panel)
Targeted Sequencing
(29-gene-panel)
Whole-exome sequencing

Table 1.2 The mutation frequencies of well-known genes in published NGS studies consisting
of paired diagnostic and relapsed DLBCL samples
Juskevicius
D, et al.

Greenawalt
DM, et al. *

Melchardt
T, et al. *

Morin
RD, et al.

Range

Total
**

COSMIC
(de novo)

Duke
study
(de novo)

D
5
8
4
12
4-12
7
11.0
R
5
19
7
8
5-19
8
D
15
15-15
15
9.0
BTG1
R
10
10-10
10
D
30
13
8
9
8-30
19
3.6
CD79B
R
25
6
11
16
6-25
18
D
5
31
20
13
5-31
13
16.0
CREBBP
R
5
42
11
20
5-42
16
D
13
16
13
13-16
14
11.0
EZH2
R
10
26
12
10-26
14
D
0
9
0-9
3
5.0
FOXO1
R
0
24
0-24
9
D
5
10
20
2
2-20
7
5.0
MYC
R
5
15
22
12
5-22
10
D
20
12
12
12
12-20
15
11.2
MYD88
R
20
19
15
20
15-20
19
D
25
22
36
14
14-36
23
12.0
PIM1
R
25
10
33
20
10-33
22
D
0
0-0
0
8.0
SGK1
R
5
5-5
5
D
4
4-4
4
8.0
STAT6
R
4
16
4-16
11
D
58
44
13
13-58
41
26.0
KMT2D
R
44
41
28
28-44
38
* The data from Greenawalt DM, et al. and Morin RD, et al. included single diagnostic/relapsed
B2M

samples
**Total = Total mutated sample number/Total sample number
D denotes diagnostic samples and R denotes relapsed/refractory samples
COSMIC (de novo) denotes the diagnostic mutation frequencies reported in the COSMIC online
dataset; Duke study (de novo) denotes the diagnostic mutation frequencies reported in the study
by Duke University, in which 1001 de novo DLBCL samples were sequenced.
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6.2
4.9
4.7
11.4
6.1
4.7
5.5
17.2
16.6
7.8
6.8
24.8
-

Chapter 2: Explore the genome landscape features in diagnostic and
relapsed/refractory diffuse large B-cell lymphoma sample pairs through whole-exome
sequencing
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Background
The current classification system is based on the patterns of gene expression to distinct
DLBCL into cell-of-origin (COO) categories, including ABC, GCB, and unclassified subtypes.
ABC and unclassified subtypes are also known as non-GCB subtypes. Different subgroups are
believed to arise from different stages of lymphoid differentiation. The non-GCB subtype arises
from the plasmablastic cells just prior to the germinal center exit, whereas The GCB subtype arises
from the centroblasts. The non-GCB subtype is mainly driven by the constitutive activation of the
NF-κB pathway, whereas the GCB subtype is driven by different abnormalities, such
as BCL2 translocation and EZH2 mutations. Extensive research has shown that non-GCB DLBCL
has a worse prognosis. Despite the dramatically improved outcome of DLBCL patients in the
immunochemotherapy era, about 30%-50% of DLBCL cases are resistant to immunochemotherapy
and have extremely poor survival outcomes. The mutation landscape or clonal evolution during the
process of disease progression is elusive.
At this point, data on sequential biopsies in DLBCL were mainly acquired through
Targeted Sequencing, which were only focused on around 20 well-known genes and essentially
blind to all the other potential genes. To date, three studies have reported WES on paired diagnostic
and relapse DLBCL samples, each with only seven, eight, and six pairs (Table 1.1). Due to the
heterogeneity of DLBCL, a systematic understanding of how evolution contributes to relapse
is restricted by the limited sample sizes. Thus, this study seeks to broaden our knowledge in the
relationship between the dynamic genomic mutations of DLBCL and its chemotherapy-resistance.
WES data from 23 diagnostic and relapsed/refractory DLBCL pairs, including 16 in-house and
seven downloaded pairs, were analyzed using the same pipeline. To the best of our knowledge, this
study systematically examined the WES data in the largest cohort with the most DLBCL diagnostic
and relapsed/refractory pairs by far.
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Results and discussion
Sample summary
Our in-house cohort and downloaded datasets were included in this study. As shown in
Table 2.1, 23 diagnostic and relapsed/refractory pairs were analyzed in this study. The in-house
cohort consisted of 16 paired diagnostic and relapsed/refractory samples with or without matched
germline (seven pairs with paired germline and nine pairs without paired germline), consisting of
both fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) samples. Among these 16
pairs, ten pairs were from the IRB 283-11, which was a prospective phase III clinical trial using the
Stat3 inhibitor Ruxolitinib in patients with relapsed/refractory DLBCL and peripheral T cell
lymphoma (PTCL). The other six pairs were acquired from the UNMC pathology tissue library.
These DLBCL patients were treated at UNMC with R-CHOP in the last ten years; paired diagnostic
and relapsed biopsy blocks were both available. To increase the robustness of our results, another
seven diagnostic and relapsed pairs were included from the downloaded datasets (SRP039525,
three pairs with paired germline and four pairs without paired germline) (Jiang et al. 2014). IHC or
Gene-Expression-Profiling (GEP) was performed to determine the subtypes. The results of
IHC and GEP were consistent in most samples, except for one sample, in which IHC was done in
both

diagnostic

and

relapsed/refractory

biopsies; GEP

was

only

performed

on

its

relapsed/refractory biopsy due to the fresh frozen tissue availability. It was classified as GCB by
IHC in both diagnostic and relapsed samples but classified as ABC by GEP profiling in the relapsed
sample. Most possibly, this case was not a subtype transfer, because the IHC results were consistent
at diagnosis and relapse. Since GEP has higher accuracy than IHC, we eventually classified this as
an ABC case as indicated by the GEP data. In addition, another 30 relapsed samples with paired
germline from publications were included as the validation cohort (Morin et al. 2016).
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Clinical characteristics
Patient and clinicopathological characteristics are summarized in Table 2.2. The median
age at diagnosis for the 23 paired samples was 61.5 yr (range 29-85 yr). The median relapse-freesurvival was 1.7 yr (range 0.3-13.2 yr). The GCB subgroup had a significantly longer relapse-free
survival than the non-GCB subgroup (5.81 yr vs. 1.82 yr, p = 0.011). No significant correlations
were identified regarding relapse-free-survival and other parameters. The non-GCB patients
comprised 68% of our cases, all of which eventually were resistant/relapsed, whereas the de novo
DLBCL population only consists of 44% of non-GCB cases, suggesting the non-GCB cases were
enriched in the relapsed/refractory cohort. None of our cases exhibited central nervous system
involvement, whereas one case experienced testicular involvement (1/10, 10%).
Tumor purity
The tumor purity of the in-house cohort was estimated by the pathologist, as well as by
CopywriteR (Kuilman et al. 2015) and SciClone (Miller et al. 2014). The median tumor purity was
43.5%, ranging from 14% to 82%. The tumor percentage was lower than other studies, but no
significantly different tumor purities were observed between the paired diagnostic
and the relapsed/refractory samples.
As mentioned, multiple methods, including pathologist, CopywriteR, SciClone as well as
calculation from the maximal VAFs observed and known copy number state of individual
mutations, were employed to estimate the tumor purity. The results obtained from each method
were not quite consistent. Each method had obvious limitations, for example, a pathologist can be
subjective, and the tumors evaluated and sequenced were not the same. There is no standard method
for tumor purity estimation yet. Since no significantly divergent purities between diagnostic and
paired relapsed/refractory samples were discovered, the analysis focused on evolution would not
be impacted dramatically by the variations from different methods.
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Number of single nucleotide variants (SNV)
The sequencing data were filtered and analyzed using a WES pipeline (see Chapter 7 for
details). The average number of single nucleotide variants (SNV) observed per patient was 481
(range 22–1607) from the primary versus 302 (range 9–1337) from the RR cohorts (p > 0.05), 168
(range 135–1261) from the FF versus, 731 (range 92–1260) from the FFPE cohorts (p > 0.05), and
113 (range 9–397) from the with-paired-germline versus 936 (range 667–1607) from the withoutpaired-germline cohorts (p < 0.00001). (Figure 2.1)
As shown, relapsed/refractory DLBCL samples carried a similar number of mutations as
compared to primary tumor biopsies. In addition, no significant differences regarding the SNV
number per sample between the FF and FFPE samples were identified, possibly because we applied
extra filters to remove FFPE false-positive variants (Chen et al. 2014). Moreover, paired germlines
reduced mutations per sample efficiently as expected (p < 0.00001). Because every healthy
individual carry recessive genetic variant, which can complicate the effort to identify the real
targetable driver mutations, these germline variants are specific for each individual and can only
be filtered by sequencing tumor and germline samples in parallel.
Genetic subtypes of DLBCL
As we mentioned, the current subtype classification is based on the cell of origin. With the
development of NGS, specifically targeting oncogenic signaling pathways became possible.
Moreover, these developments in NGS have heightened the need for precise medicine. Thereby, a
new classification system based on genomic abnormalities was established recently to gain insight
into potential therapeutic strategies (Schmitz et al. 2018). This study included 574 de novo DLBCL
biopsies, on which WES, transcriptome sequencing, array-based DNA copy-number analysis, and
targeted amplicon resequencing were performed. Then, an algorithm to discover genetic subtypes
based on the co-occurrence of genetic alterations was developed and implemented. Forty-six-point
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six percent of all cases were successfully classified, and four genetic subtypes were identified. Each
subgroup has distinct underlying molecular mechanisms.
1. The MCD subgroup was based on the co-occurrence of MYD88 and CD79B mutations
and mainly in the ABC subtype.
This subgroup was driven mainly by the BCR activation and its downstream NF-κB
activation. The commonly mutated genes in this subgroup included CD79A/B,
MYD88, and BCR signaling regulators, such as LAPTM, LYN, PTPN6, GRB2, PRKCD,
DGKZ, SLA, and MAP4K1, as well as NF-κB regulators, such as A20, CARD11,
BCL10, and MALT1. Genes regulated by MYC were enriched in this subgroup, as a
proliferation signature. Immune editing genes such as CD58 were mutated frequently
in this subgroup.
2. The BN2 subgroup was based on the BCL6 fusions and NOTCH2 mutations. The
NOTCH pathway inhibitors SPEN and DTX1 were frequently mutated in this subgroup.
The BN2 cases were remarkably enriched in the unclassified subtype. Mutations of
NF-κB regulators were common.
3. The N1 subgroup was based on the NOTCH1 mutations and aberrations targeting
transcriptional regulators of B-cell differentiation, such as IRF4, ID3, and BCOR. The
N1 cases were discovered mainly in the ABC subtypes. NOTCH1 and NOTCH2
mutations increase their protein stability, while SPEN and DTX1 mutations promote
the transcriptional activity. As a result, the NOTCH pathway is activated. Recent
evidence revealed NOTCH1 and NOTCH2 worked through distinct pathogenic
pathways. The evidence suggests that NOTCH1 mutations primarily occurred in the
ABC subgroup, whereas NOTCH2 mutations were clustered in the unclassified
subgroup; no NOTCH1 mutations co-occur with NOTCH2 mutations. However, the
differences between NOTCH1 and NOTCH2 pathways are elusive.
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4. The EZB subgroup was based on the EZH2 mutations and BCL2 translocations and in
this subgroup, cases were mainly the GCB subtype. In this group, alterations of BCL2
and epigenetic regulators such as EZH2 and EP300 are the main pathogenic cause. The
upstream regulators include PTEN, PI3K, AKT, mTOR, GNA13, RHOA, JAK-STAT,
etc.
As mentioned, this study was conducted in de novo DLBCL. However, no studies have
investigated the genetic subtypes of relapsed/refractory DLBCL. To address the composition of
relapsed/refractory DLBCL according to the genetic classification, we applied this novel
classification in our relapsed/refractory DLBCL cohort for the first time. The results are shown in
Figure 2.2A.
Consistent with the published data (47%), the new genetic classification method
successfully classified 52% of our cases (12/23, p = 0.76). Most of the genetic classification of the
diagnostic samples was consistent with that of their paired relapsed/refractory samples (10/12).
Surprisingly, one case exhibited a subtype drift from MCD at diagnosis to BN2 at relapse. By far
there has been no report about the novel subtype transfer yet.
No significant differences were identified between our data and the published data
regarding the percentage of EZB, BN2, or N1 subgroups. Interestingly, 30% of our cases were
MCD, which was significantly higher than the published data (8%, p = 0.0024).
To further confirm these findings, the 30 relapsed only downloaded cases were analyzed
as well (Figure 2.2B). The MCD subtype still had a significantly higher percentage (27%) than the
publication (8%, p = 0.0030). These results suggested the MCD group is enriched in the
relapsed/refractory cohort than the de novo DLBCL population. A possible explanation for this
might be that the MCD group is prone to relapse. Targeting MCD abnormalities can be a potential
therapeutic strategy for many relapsed/refractory cases. However, with the relatively small sample
size, caution must be applied. Further validations in larger relapsed/refractory cohorts are needed.
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To dissect the distribution of genetic subtypes in the gene-expression subgroups, the new
classification method was implemented in our non-GCB (16) and GCB (7) cases separately (Table
2.3A, C). The majority of the successfully classified non-GCB cases (9/16, 56%) were MCDs (5/9,
56%), comprising 31% of all non-GCB cases. This can be explained by the fact that MYD88
mutations, the hallmarks for the MCD subtype, are mainly clustered in the non-GCB subgroup.
There was a trend that the MCD mutations were enriched in our non-GCB cases (31% vs. 18%).
However, most possibly limited to the sample size, p value was not significant (p = 0.1849). The
validation cohort (30 relapsed samples with paired germline) showed similar results, with
significantly more MCDs than the published non-GCB data as well (56% vs. 18%, p = 0.0138)
(Table 2.3B). As a summary, the MCD cases were enriched in the relapsed/refractory non-GCB
subgroup than the de novo non-GCB subgroup.
Interestingly, our GCB cases also had more MCD cases than the published GCB cases
(29% vs. 0%, p = 0.0004) (Table 2.3C). The validation cohort confirmed the higher percentage of
MCDs in the GCB cases as well (15% vs 0%, p = 0.0002) (Table 2.3D). The results suggest that
GCB with MCD mutations were probably more resistant. This finding was unexpected and must
be interpreted with caution. Possible sources of bias included:
1. False-positive variants were present
2. IHC subtype classification was not accuracy
Additionally, the MCD subgroup was prone to be more related to extranodal involvement
in the de novo DLBCL study (28% vs. 15%, p = 0.051) (Schmitz et al. 2018). This is possibly
because MYD88 and CD79B mutations are common in extranodal lymphomas, such as primary
central nervous system lymphoma. However, this trend was not identified in our data (14% vs. 6%,
p = 0.52). None of our cases was primary central nervous system lymphoma, which may be biased
from the limited sample size. One case experienced testicular involvement and was classified as
the MCD subgroup.
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Genomic landscape
The mutation frequencies of well-known DLBCL-related genes in our diagnostic samples
were mostly consistent with what were reported for de novo cases in the Cosmic database, except
for MYD88 mutations, which were significantly enriched in our samples (11.2% vs 34.8%, p =
0.003) (Figure 2.3A). This finding was further validated by comparing our data to the Duke study
data, in which 1001 de novo DLBCL samples were sequenced (Figure 2.3B) (Reddy et al. 2017).
The same trend was revealed that the MYD88 mutations were enriched in the diagnostic pool of the
relapsed/refractory cohort (17.2% vs. 34.8%, p = 0.029). Consistent with our previous observation
that the MCD cases were enriched in the relapsed/refractory DLBCL patients, these results
suggested the cases with MYD88 mutations were possibly prone to relapse. Surprisingly, the PIM1
mutation frequency in our diagnostic cohort was significantly lower (p < 0.05).
The mutation frequencies of these well-known DLBCL-related genes were investigated in
non-GCB and GCB cases separately in both Duke study and our cohort. There were similar trends
in both subtypes that our cohort had more MYD88 mutations. However, most possibly due to the
limited case number in our cohort, no statistical significance was observed (Figure 2.3C, D).
The top mutated genes were shown in the heatmap (Figure 2.4). The heatmap was grouped
according to the major pathogenic pathways into NF-κB, NOTCH, Epigenetic and Other pathways
(TP53, JAK-STAT, PI3K, immune escape, etc.).
The most frequently mutated genes in our diagnostic group were MYD88 (35%), HLA-A
(52%), HLA-B (26%), EEF1A1 (26%), CRIP1 (22%), CREBBP (17%), LAMA5 (17%), MYBPC2
(17%), KMT2D (17%), EP300 (17%), and ARID1A (17%). Meanwhile, that in the
relapsed/refractory pool were almost the same genes with slightly change in the frequencies:
MYD88 (30%), HLA-A (43%), HLA-B (30%), CRIP1 (22%), CREBBP (22%), LAMA5 (22%),
MYBPC2 (22%), KMT2D (17%), EP300 (17%), ARID1A (17%) and BCL2 (17%). In the non-GCB
subgroup, MYD88 was the most frequently mutated gene in both diagnostic and relapsed/refractory
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cases besides HLA (diagnosis at 40%; relapse at 33%). In the GCB subgroup, the most frequently
mutated genes were CREBBP(43%), MYBPC2(43%), EP300(43%), and ARID1A(43%) in the
diagnostic samples and MYBPC2(57%), CREBBP (43%), EP300 (43%), and ARID1A(43%) in the
relapsed/refractory cases.
NF-κB group mainly involved proximal BCR activation genes, such as CD79B, MYD88,
and NF-κB and its regulators, such as CARD11, BCL10, NFKBIE, NFKBIA, etc. According to
Schmitz R, et al, MCD cases were dominant in this group, yet BN2 and EZB cases could be present
as well. The mutations in this group occurred in most of the cases, accounting for 70% of the
diagnostic cases and 78% of the relapsed/refractory cases. As a hallmark of the MCD subtype, the
co-occurrence of MYD88 and CD79B mutations were only found in one diagnostic sample (1/23,
4%) and two relapsed/refractory samples (2/23, 9%). They were classified as MCD cases.
The mutation frequency of MYD88 had a minimal change from 35% at diagnosis to 30%
at relapse, with 40% to 33% in the non-GCB subgroup and no change in the GCB subgroup.
Overall, five out of eight patients with MYD88 mutations carried L265P. As mentioned, located in
the hydrophobic core of TIR, this mutation possibly changed the three-dimensional structure of
TIR and enhanced its binding affinity to the TLR. It was reported to be independently associated
with poor outcomes in DLBCL patients, but previous studies of MYD88 L265P have not dealt with
its role in resistance. The VAF of L265P exhibited evolutions in four out of five pairs. These results
suggest MYD88 L265P is highly aggressive and its evolution plays a vital role in the DLBCL
relapse. Data from previous studies were limited to the recurrence and prognostic value of L265P,
but rarely any clues on its genetic evolution. Another well-known MYD88 mutation, S219C, was
in two patients. However, no consistent evolution trend was observed.
CD79B mutations were all discovered in the ABC subgroup, with 6.67% in the diagnostic
and 13.33% in the relapsed/refractory ABC samples. The hot-spot mutation CD79B Y196X was not
discovered in our data, but CD79B Y197X was recurrent in two patients. It is a hot spot mutation in
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the ITAM domain as well, repressing its negative regulation by the kinase LYN. No consistent
evolution trend was revealed.
NFKBIE mutations were observed in two relapsed/refractory and one diagnostic sample.
NFKBIA mutations were observed in one relapsed sample only. Interestingly, the VAFs of all their
mutations increased (NFKBIA from 0% to 20.5%; NFKBIE from 0% to 68.8%, and from 1.0% to
24.1%). NF-κB inhibitor family including NFKBIA, NFKBIE, and NFKBIZ represses the NF-κB
pathway by sequestering NF-κB in the cytoplasm.(Coto et al. 2018, Lundbo et al. 2016, CotoSegura et al. 2019) In consequence, NF-κB as a transcription factor is not able to translocate to the
nucleus and bind to DNA. NFKBIA, NFKBIE, and NFKBIZ encode IκBα, IκBε, and IκBζ
separately. Both NFKBIA and NFKBIE mutations are common in Hodgkin Lymphoma Reed–
Sternberg cells, whose NF-κB pathway is constantly active.(Mansouri et al. 2016) NFKBIE
mutations were reported in about 4% of the de novo DLBCL patients and associated with inferior
survival.(Mansouri et al. 2016) NFKBIZ mutations, clustered in the 3’-UTR, were recently
identified as a potential novel mechanism of oncogene deregulation of NF-κB in the DLBCL as
well.(Morin et al. 2016) But no NFKBIZ mutations were detected in our cohort.
SHARPIN (SHANK-associated RH domain interacting protein) and PTPN14 (non-receptor
tyrosine phosphatase 14) were among the top mutated genes that not well studied yet. Both play
important roles in the regulation of the NF-κB pathway. We will discuss them in detail in a
subsequent section.
NOTCH pathway was newly addressed in the genetic subtype classification study. It
included both NOTCH and NOTCH2 pathways, which were reported to be distinct, but their
differences are still vacillating. NOTCH pathway was mutated mainly in BN2 and N1
subgroups.(Schmitz et al. 2018)
MAML2, a coactivator of NOTCH targets(Arruga, Vaisitti and Deaglio 2018, Gu, Masiero
and Banham 2016), was the top mutated gene in this group, which were detected in 17% of the
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diagnostic samples and remained 17% in the relapsed/refractory samples. All the VAFs of its
mutations increased at relapse. These results suggest MAML2 mutations play a critical role in
DLBCL relapse.
SPEN, an inhibitor of NOTCH-dependent gene expression by modifications of
histone(Arruga et al. 2018, Gu et al. 2016), was mutated in our non-GCB subgroup only.
Consistently, SPEN as well as NOTCH2 mutations were discovered by Schmitz R, et al as
hallmarks of BN2 subtype, which was enriched in the unclassified cases. In our data, G15935811A
and C15929001T both showed significantly increased VAF (from 0.4 to 0.62; from 0.12 to 0.40).
But their molecular mechanisms are unclear.
The epigenetic group consists of histone methyltransferases (e.g. KMT2D), histone
acetyltransferases (e.g. CREBBP and EP300), PRC2 complex (e.g. EZH2), SWI/SWF complex
(e.g. ARID1A), etc.(Cheng et al. 2019) EZB subgroup often carries epigenetic gene
mutations.(Schmitz et al. 2018)
Histone acetyltransferases CREBBP and EP300 were the most frequently mutated genes in
this group. As expected, CREBBP mutations were more frequent in the GCB group, with 43% of
GCB and 7% non-GCB cases carrying its mutations at diagnosis. The mutations expanded in the
non-GCB subgroup to 13% in the relapsed/refractory cases and remained the same frequency in
the GCB subgroup. The hot-spot mutation S1680 discussed in Chapter 1 was not identified in our
cohort. Two known inactive mutations, R1446L and D1435E, were discovered in two cases
separately. R1446 binds directly to the ligands and D1435 is in the L1 substrate-binding loop of
the histone-acetyltransferase domain. Thus, these two mutations are predicted to disrupt the transfer
of acetyl groups to histones, thereby regulating chromatin dynamics. In our study, their VAF both
changed minimally from diagnosis to relapse (R1446L VAF from 0.67 to 0.51; D1435E VAF from
0.03 to 0.05), which may be caused by treatment effects, the variation of tumor purity or sequencing
bias. Thus, it is hard to inter whether R1446L or D1435E are resistant based on the current data.
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The mutation frequency of KMT2D, a histone methyltransferase, was 17.39% in our
diagnostic samples and remained the same in our relapsed/refractory samples. The mutation
frequency in de novo DLBCL was consistent with that reported in the Cosmic dataset (17.39% vs.
25.59%, p = 0.47). No recurrent mutations were discovered in our study.
Mutations of PRC2 complex components EZH2 and JARID2 were detected, but not in as
many cases with mutated histone methyl/ acetyltransferases. EZH2 mutations were detected in
one case at diagnosis (4.34%, 1/23) and two cases at relapse (8.70%, 2/23), with a gain of
mutations in a GCB case. Variants in both cases were the hot-spot mutation Y646X (Y646F/N)
and showed remarkable evolution on VAF (7.69% to 40.4%, and 0% to 30.9%), suggesting EZH2
Y646F/N mutations are resistant to R-CHOP chemotherapy. As mentioned in Chapter 1, EZH2
mutations are reported to primarily happen at Y646 in the STEM domain and they are commonly
gain-of-function. Y646X mutations increase the H3K27-trimethylation because substitutions with
smaller amino acids (asparagine, serine, histidine, phenylalanine, and cysteine, etc.) at Y646
creates a bigger catalytic pocket for H3K27 to freely rotate and form bonds.
SWI/SNF complex member ARID1A mutations were predominantly in GCB (non-GCB
6.67% vs GCB 42.86% in both diagnostic and relapsed/refractory samples). ARID1A mutations’
VAF increased in all 6 pairs, except for one case pair with an insertion mutation.
Moreover, many other pathways are critical in DLBCL pathogenesis, but lacking data in
relapsed/refractory DLBCL, such as immune escape pathway, PI3K-AKT-mTOR pathway, TP53
pathway, and JAK-STAT pathway, etc. Here we also investigated the mutation profiles of these
genes.
In our study, genes related to immune escape, such as HLA, B2M, CD58, CIITA, etc., were
frequently mutated. B2M 44711583delCT was a recurrent deletion leading to a frameshift. This
mutation resided in 2 case pairs, both of which had VAF evolutions (from 0% to 49.02%, from 0%
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to 46.58%). This mutation was frequently detected in colon cancers. Though frequently reported in
DLBCL sequencing studies, it has never been related to relapse.
TP53 mutation is an independent prognosis predictor for DLBCL. In our data, TP53
mutations were all clustered in the GCB subgroup (28.57% at diagnosis; 42.86% at relapse). This
was an unexpected outcome, but consistent with the results by Zijun YX et. al (ref:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496956/), claiming the prognostic value of TP53
was limited within the GCB subgroup. Among the three TP53 mutations in three paired samples,
two of them persisted stably, and the other mutation D259N evolved significantly from 0% to
68.29%.
The overall mutation frequency of CCND3 increased from 0% of the diagnostic samples
to 14.29% of the relapsed/refractory samples in the GCB subtype and remained 6.67% in the nonGCB subtype at both diagnosis and relapse. One case pair carried a reported recurrent missense
mutation, affecting a threonine residue at position 283 (T283). It was confirmed to be somatic and
regulate cyclin D3 protein degradation by phosphorylation at this site. In cell lines, cells transduced
with the T283 mutant had a remarkable proliferative advantage. This T283A mutation in our data
had a significant evolution after treatment, with the VAF from 0% to 35.71%. The results suggested
the T283A mutation was resistant.
However, PIM1 S188X or STAT6 D419G, the other two hot-spot mutations discussed in
Chapter 1, were not identified in our cohort.
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Figures
Figure 2.1 The average number of single nucleotide variants (SNV) observed per sample
The box-plot diagrams included the median values and the interquartile ranges. No significant
differences regarding the SNV number per sample between the diagnostic and relapsed/refractory
samples were identified. In addition, no significant differences regarding the SNV number per
sample between the FF and FFPE samples were identified, possibly because we applied extra filters
to remove FFPE false-positive variants. The SNV number per sample was significantly higher in
the samples without germlines than the samples with germlines. The paired t-test was applied when
the results were compared in the diagnostic and relapsed/refractory samples. Results were
compared using Student’s t-test in the FF vs. FFPE and With Germline vs. Without Germline
comparison groups. FF denotes fresh frozen samples and FFPE denotes formalin-fixed paraffinembedded samples. *** denotes p < 0.001.
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Figure 2.2 The MCD subgroup was enriched in the relapsed/refractory cohorts according to
the genetic subtype classification
(A) The MCD subgroup was enriched in the 23 paired diagnostic and relapsed/refractory samples.
The left pie chart shows the genetic subtype classification in the 23 paired diagnostic and
relapsed/refractory samples and the right pie chart shows the published genetic subtype
classification in the de novo DLBCL cohort. The results of the new genetic classification were
consistent between the diagnostic and relapsed/refractory samples in the 23 pairs, except for one
case with a subtype drift from the MCD at diagnosis to the BN2 at relapse. The MCD subgroup
was significantly more enriched (7/23, 30%) in the relapsed/refractory cohort than the published
de novo cohort (46/574, 8%). The percentages of other subgroups in the relapsed/refractory cohort
were not significantly different from the published data. ** denotes p value less than 0.01.
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(B) The MCD subgroup was enriched in the 30 downloaded relapsed samples. The left pie chart
shows the genetic subtype classification in the 30 downloaded relapsed samples and the right pie
chart shows the published genetic subtype classification in the de novo DLBCL cohort. Consistent
with the results in the 23 pairs, the MCD subgroup was significantly more enriched (8/30, 27%) in
the relapsed cohort than the published de novo cohort (46/574, 8%). The percentages of other
subgroups in the relapsed cohort were not significantly different from the published data. **
denotes p value less than 0.01.
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Figure 2.3 The MYD88 mutations were enriched in the relapsed/refractory cohorts
Our diagnostic cases were either resistant to the initial immunochemotherapy or relapsed after
treatments, whereas cases the COSMIC database reported were randomly sampled from de novo
DLBCL population.
(A) The comparison of the mutation frequencies of well-known genes between the COSMIC
dataset and our diagnostic cohort. The MYD88 mutation frequency was significantly higher in our
diagnostic cohort (35% vs. 11%, p < 0.05).
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(B) Comparison of the mutation frequencies of well-known genes between the DUKE study and
our diagnostic cohort. The MYD88 mutation frequency was significantly higher in our diagnostic
cohort (35% vs. 17%, p < 0.05). No PIM1 mutations were detected in our diagnostic samples (p <
0.05), which may be due to the limited sample size.
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(C) Comparison of the mutation frequencies of well-known genes in the non-GCB cases between
the DUKE study and our cohort. The MYD88 mutation frequency was prone to be higher in our
diagnostic non-GCB cases but not statistically significant, possibly due to the limited sample size
(40% vs. 30%, p > 0.05). No PIM1 mutations were detected in our diagnostic samples (p < 0.05).
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(D) Comparison of the mutation frequencies of well-known genes in the GCB cases between the
DUCK study and our cohort. Similarly, the MYD88 mutation frequency was prone to be higher in
our diagnostic non-GCB cases, but not statistically significant (25% vs. 12%, p > 0.05). The
unexpected high mutation frequency of MYD88 in the GCB cases may be due to false-positive
variants or the restricted accuracy of the subgroup classification method based on IHC. The
CREBBP mutations were significantly more enriched in our diagnostic GCB samples (p < 0.05).
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Figure 2.4 Mutation heatmap of the 23 paired diagnostic and relapsed/refractory samples
The red blocks indicate mutated genes and the white blocks indicate wild-type genes. D denotes
diagnostic samples and R denotes relapsed/refractory samples. One patient with COO subgroup
drift was labeled in yellow, which was classified as a non-GCB case at diagnosis and a GCB case
at relapse. Another patient with genetic subgroup drift was labeled in brown, which was classified
as an MCD case at diagnosis and a BN2 case at relapse.
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Tables
Table 2.1 Sample summary
Totally 23 diagnostic and relapsed/refractory pairs were analyzed, among which ten pairs were
from the clinical trial IRB 283-11, six pairs were from the UNMC pathology dataset, and seven
pairs were downloaded from the SRA platform. As a validation cohort, the data of the other 30
relapsed cases were obtained from the authors of a published study (Morin et al. 2016).
Cohorts
Our datasets
Downloaded datasets

IRB 283-11
UNMC database
SRP039525
PMID26647218
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Samples
Total
10 pairs
6 pairs
23 pairs
7 pairs
30 relapsed cases

Table 2.2 Patients’ clinical characteristics
Characteristics
Age at diagnosis (years)
Range
Median
≤ 60
> 60
Relapse-free survival (years)
Range
Median
Gender
Male
Female
Subtype
Non-GCB
GCB
Matched Germline DNA
Yes
No
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No. (%)
29-85
61.5
9/20 (45%)
11/20 (55%)
0.3-13.2
1.7
10/20 (50%)
10/20 (50%)
15/22 (68%)
7/22 (32%)
10/23 (43%)
13/23 (57%)

Table 2.3 The MCD subgroup was enriched in both non-GCB cases and GCB cases of the
relapsed/refractory cohort
The published data were from the study reporting the novel genetic classification on 574 de novo
DLBCL cases (Reddy et al. 2017). p values were calculated using the Student’s t-test or Chi-square
test. * denotes p values less than 0.05 and *** denotes p values less than 0.001.
(A) The MCD subgroup was prone to be enriched in the non-GCB cases of our relapsed/refractory
cohort. p value was not significant, possibly due to the small sample size.

Unclassified by the new method
Classified by the new method
EZB
BN2
MCD
N1
subtype drift

Our cohort
7/16 (44%)
9/16 (56%)
1/16 (6%)
0/16 (0%)
5/16 (31%)
0/16 (0%)
1/16 (6%)

Published data
142/250 (57%)
107/250 (43%)
5/250 (2%)
47/250 (19%)
44/250 (18%)
12/250 (5%)
0/250 (0%)

p value
0.4400
0.3133
0.0837
0.1849
1.0000
0.0602

(B) The MCD subgroup was enriched in the non-GCB cases of the 30 downloaded relapsed cases.

Unclassified by the new method
Classified by the new method
EZB
BN2
MCD
N1

Downloaded
relapsed
cohort
3/9 (33%)
6/9 (67%)
0/9 (0%)
1/9 (11%)
5/9 (56%)
0/9 (0%)
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Published data
142/250 (57%)
107/250 (43%)
5/250 (2%)
47/250 (19%)
44/250 (18%)
12/250 (5%)

p value
0.1900
1.0000
1.0000
*0.0138
1.0000

(C) The MCD subgroup was enriched in the GCB cases of our relapsed/refractory cohort. The N1
subgroup had a significantly higher percentage in our relapsed/refractory cohort as well.

Unclassified by the new method
Classified by the new method
EZB
BN2
MCD
N1

Our cohort
2/7 (29%)
5/7 (71%)
1/7 (14%)
1/7 (14%)
2/7 (29%)
1/7 (14%)

Published data
165/324 (51%)
159/324 (49%)
120/324 (37%)
39/324 (12%)
0/324 (0%)
0/324 (0%)

p value
0.28
0.4295
0.5976
***0.0004
*0.0212

(D) The MCD subgroup was enriched in the GCB cases of the 30 downloaded relapsed cases.

Unclassified by the new method
Classified by the new method
EZB
BN2
MCD
N1

Downloaded
relapsed
cohort
11/20 (55%)
9/20 (45%)
6/20 (30%)
0/20 (0%)
3/20 (15%)
0/20 (0%)
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Published data
165/324 (51%)
159/324 (49%)
120/324 (37%)
39/324 (12%)
0/324 (0%)
0/324 (0%)

p value
0.9019
0.6930
0.1458
***0.0002
1.0000

Chapter 3: Investigate the mutation evolution patterns in the paired diagnostic and
relapsed/refractory samples
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Background
Recently, there has been an increasing of interest in the evolution pattern of DLBCL. It is
unknown whether DLBCL relapse was mainly due to original mutations, or novel variants induced
by chemotherapy, or other reasons. Several attempts have been made to explore the mutation
evolution patterns in DLBCL (Juskevicius et al. 2016, Melchardt et al. 2016). However, most
studies have only been carried out in a small number of cases. To our knowledge, our cohort has
the largest number of diagnostic and relapsed case pairs. Thus, we try to dissect the evolution
pattern in our cohort.
Results
Top evolved genes
In 23 sample pairs, the genes evolved most overall were PIM1 (from 0% to 9%), TMSB4X
(from 0% to 9%), and BCL6 (from 0% to 9%) (Table 3.1A); in the non-GCB group was TMSB4X
(from 0% to 13%) (Table 3.1B); and in the GCB group was B2M (from 0% to 29%) (Table 3.1C).
Most of the top evolved genes were already well-studied, except for TMSB4X gene which will be
discussed in detail in a subsequent section.
Two major evolution patterns were identified
Utilizing the Venn diagram, two major mutation patterns were identified in our cohort
(Pattern 1 and Pattern 2) (Figure 3.1). The detailed method is described in Chapter 7. In Pattern1,
diagnostic and relapsed/refractory mutations were mostly overlapped, indicating the initial
mutations were resistant and survived the chemotherapy. Five out of 13 (38%) cases were classified
in the Pattern 1. Pattern 2 had a considerable part of novel mutations induced during the
immunochemotherapy process, and only present in the relapsed/refractory samples. Eight out of 13
(62%) cases fitted in the Pattern 2.
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Correlations between evolution patterns and clinical characteristics
The correlations between the clinical characteristics and evolution patterns were analyzed
(Figure 3.2).
First, Pattern 2 patients were significantly younger at diagnosis (Pattern 1 : median 74,
range 64-80 yr; Pattern 2 : median 57, range 54-69) and relapse (Pattern 1 : median 80, range 7593 yr; Pattern 2 : median 62, range 56-70) than Pattern 1 patients.
Second, non-GCB cases were possibly enriched in the Pattern 2 (p = 0.05). In Pattern 1,
non-GCB cases comprised 50% of all cases. Meanwhile, Pattern 2 involved 60% non-GCB cases.
Third, the Pattern 2 patients had significantly less SNVs per sample (p < 0.05). The median
SNV number per diagnostic sample was 669 in Pattern 1 (range 386-703), whereas that in Pattern
2 was 151 (range 88-1607) (p = 0.036). The median SNV number per relapsed/refractory sample
was 676 in Pattern 1 (range 393-757), whereas that in Pattern 2 was 162 (range 112-684) (p =
0.019). The number of shared SNVs between diagnostic and paired relapsed/refractory sample was
significantly smaller in Pattern 2 as well (Pattern 1: median 595, range 328-646; Pattern 2: median
77, range 32-637; p = 0.014).
What is more, Pattern 2 patients had relatively shorter relapse-free-survival (Pattern 1 :
median 10.71yr, range 6.33-13.23 yr; Pattern 2 : median 1.35 yr, range 0.30-6.67 yr; p = 0.024),
especially the non-GCB cases with Pattern 2 (median 0.78 yr, range 0.3-3.5 yr).
Discussion
Mainly two different patterns (Pattern 1 and 2) were identified in our cohort by Venn
Diagram. The possible mechanisms for the relapse of these two patterns were distinct: in Pattern 1,
the resistant mutations were mostly from the paired original sample, and survived the
immunochemotherapy; in Pattern 2, the resistant mutations were induced by the treatment stress.
This finding is generally consistent with the hypothesis from the other studies.
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To our knowledge, this is the first study showing the Pattern 2 was correlated to a worse
prognosis. The patients exhibiting Pattern 2 were diagnosed at a significantly younger age and had
significantly shorter time before relapse, especially the non-GCB cases with Pattern 2. The
mechanisms underlying this observation are elusive. This result is valuable for better precise
treatment for DLBCL patients. A non-GCB DLBCL patient with Pattern 2 may subject to more
aggressive therapies.
In addition, the SNV number per sample was relatively lower in the Pattern 2 patients (p
< 0.05), suggesting a possible distinct genomic environment between Pattern 1 and 2. Some studies
suggested the number and distribution of SNV can impact the disease pathogenesis and progression
(Yu et al. 2017). Whether this genomic background contributes to the relapse and prognosis of
DLBCL is unclear. Our results are primary, and future work needs to be done to establish whether
and how SNV number or distribution contributes to the DLBCL relapse.
Even though the cases were classified into two distinct evolutional patterns, we noticed
most variants were shared between diagnostic and relapsed/refractory samples (shared/diagnostic
SNV number : median 58%, range 3%-92%), suggesting positive selection, not drift, might be the
major force shaping clonal hematopoiesis.
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Figures
Figure 3.1 Two evolution patterns identified in the paired diagnostic and relapsed/refractory
DLBCL cases
The Venn diagrams were generated based on the presence of each mutation in the sample pairs.
The blue circle denotes diagnostic variants and the yellow circle denotes relapsed/refractory
variants. In the Pattern 1 cases, almost all the relapsed/refractory variants were from its diagnostic
sample, while in the Pattern 2 cases, a considerable portion of the relapsed/refractory variants were
induced by treatments. The cut-off of 70% was used regarding the percentage of resistant alterations
in the relapsed/refractory samples inherited from the matched diagnostic samples. The ratios of
shared to relapsed/refractory variants were significantly higher in the cases with Pattern 1 (p <
0.05).
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Figure 3.2 Comparison of clinical characteristics between the two evolution patterns
(A) The patients with Pattern 2 were significantly younger than these with Pattern 1 both at
diagnosis and at relapse. * denotes p values less than 0.05.
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(B) The patients with Pattern 2 had significantly less SNVs per sample than these with Pattern 1.
The shared SNVs between the matched diagnostic and relapsed/refractory samples were also
significantly less in the cases with Pattern 2. * denotes p values less than 0.05.
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(C) The relapse-free survivals in the cases with Pattern 2 were significantly shorter than these
with Pattern 1. * denotes p values less than 0.05.
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Tables
Table 3.1 The top evolved genes identified in our cohort included BCL6, PIM1, TMSB4X,
and B2M
D denotes diagnostic samples and R denotes relapsed/refractory samples. Diff (R-D) denotes the
differences between the matched diagnostic and relapsed/refractory samples regarding the mutation
frequencies of a specific gene. The TMSB4X was among top evolved genes in both the total cohort
and the non-GCB cohort, but its role in DLBCL pathogenesis and relapse/resistance has barely
been studied.
(A) The top evolved genes in the total cohort (23 pairs) included BCL6, PIM1, and TMSB4X
Gene
BCL6
PIM1
TMSB4X
HLA-B
B2M
CCND3
CXCR5
EZH2
LAMA5
MYBPC2
TNFRSF14
TP53
ZFP36L1
BCL2
CD79B
CREBBP

D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D

Mutation frequency
0.00
R
0.00
R
0.00
R
0.26
R
0.09
R
0.04
R
0.04
R
0.04
R
0.17
R
0.17
R
0.04
R
0.09
R
0.00
R
0.13
R
0.04
R
0.17
R
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0.09
0.09
0.09
0.30
0.13
0.09
0.09
0.09
0.22
0.22
0.09
0.13
0.04
0.17
0.09
0.22

Diff (R-D)
0.09
0.09
0.09
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04

(B) The top evolved gene in our non-GCB cohort was TMSB4X
Gene
TMSB4X
BCL6
PIM1
BCL2
CD79B
CREBBP
ETV6
IRF8
NFKBIE
NOTCH2
TNFAIP3
EBF1
MPEG1

D
D
D
D
D
D
D
D
D
D
D
D
D

0.00
0.00
0.00
0.07
0.07
0.07
0.07
0.00
0.00
0.00
0.07
0.00
0.47

Mutation frequency
R
R
R
R
R
R
R
R
R
R
R
R
R

0.13
0.07
0.07
0.13
0.13
0.13
0.13
0.07
0.07
0.07
0.13
0.07
0.53

Diff (R-D)
0.13
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07

(C) The top evolved gene in our GCB cohort was B2M
Gene
B2M
BCL6
PIM1
HLA-B
CCND3
CXCR5
EZH2
LAMA5
MYBPC2
TNFRSF14
TP53
ZFP36L1

D
D
D
D
D
D
D
D
D
D
D
D

Mutation frequency
0.00
R
0.29
0.00
R
0.14
0.00
R
0.14
0.29
R
0.43
0.00
R
0.14
0.00
R
0.14
0.00
R
0.14
0.14
R
0.29
0.43
R
0.57
0.14
R
0.29
0.29
R
0.43
0.00
R
0.14
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Diff (R-D)
0.29
0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.14

Chapter 4: The canonical NF-κB signalling pathway plays a critical role
in DLBCL relapse
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Background
The NF-κB pathway is one of the critical pathogenic pathways in DLBCL, especially the
ABC subtype. It consists of canonical and non-canonical pathways (Figure 4.1). The canonical NFκB pathway is triggered by signals from immune receptors, which activate the kinase TAK1. TAK1
then activates IKKβ, phosphorylating IκBα or p105, which sequester NF-κB members in the
cytoplasm. Upon phosphorylation by IKK, IκBα and p105 are targeted for ubiquitin-dependent
degradation, resulting in the nuclear translocation of canonical NF-κB family members, in the form
of various dimeric complexes, including RELA–p50, c-REL–p50, and p50–p50. By contrast, the
non-canonical NF-κB pathway selectively responds to a subset of tumor necrosis factor receptor
(TNFR) superfamily members and causes the activation of NIK. NIK phosphorylates and activates
IKKα, which in turn phosphorylates p100, leading to the nuclear translocation of p52 and RELB.
In the process of analysis, we found the mutations of NF-κB pathway genes were dominant in our
paired diagnostic and relapsed/refractory cases.
As shown in our mutation heatmap in Chapter 2, around 70% of all diagnostic samples
carried NF-κB pathway mutations and almost 80% of the relapsed/refractory samples carried NFκB pathway mutations. The mutation frequency in the non-GCB subgroup evolved from 67% at
diagnosis to 80% at relapse. Yet, the mutation frequency remained 71% in both diagnostic and
relapsed/refractory GCB cases. See a detailed description of NF-κB pathway mutations in section
one. Here, we further investigated the NF-κB pathway mutations and discovered three novel targets
potentially playing critical roles in the resistance of DLBCL.
Results and discussion
Significant pathway analysis
What is more, the significant pathway analysis by DAVID (Huang, Sherman and Lempicki
2009b, Huang, Sherman and Lempicki 2009a) confirmed the evolution of the NF-κB pathway from
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the diagnosis to the relapse. As shown in Figure 4.2A, many vital pathways were revealed as
significant pathways by DAVID (p < 0.05). In diagnostic samples, the top pathways with the
smallest p value included signal transduction, G2/M checkpoint, and calcium signaling pathway,
etc.; in relapsed/refractory samples, that included Erk1/Erk2 Mapk signaling pathway, graft-versushost disease, and antigen processing and presentation, etc.; the top pathways identified in both
diagnostic and relapsed/refractory samples included Notch signaling pathway, cell adhesion, and
microRNAs in cancer, etc.
Interestingly, NF-κB activation was identified as a significant pathway in the
relapsed/refractory cohort only (p = 0.034). The fold enrichment was increased by 35% in the
relapsed/refractory cases (2.32 vs 1.72 folds). These findings support that NF-κB pathway
mutations are critical for DLBCL relapse.
Potential novel target genes
The heatmap showed SHARPIN and PTPN14 among top mutated genes. There are 22% of
all diagnostic and 26% of all relapsed/refractory samples carrying SHARPIN mutations, which were
predominantly in the non-GCB subtype. PTPN14 mutations were present in 17% of diagnostic as
well as relapsed/refractory samples. Interestingly, all the PTPN14 mutations occurred in the nonGCB cases. Both SHARPIN and PTPN14 play roles in the regulation of the NF-κB pathway.
However, their roles in the DLBCL pathogenesis or relapse have not been well studied yet. Another
potential novel target we are interested in is TMSB4X. As mentioned, TMSB4X was among the top
evolved genes in all the cases (from 0% to 9%), as well as in the non-GCB group (from 0% to
13%). Most of the top evolved genes have been well-studied, but little is known about the TMSB4X
gene in DLBCL. Here, we will discuss the potential roles of SHARPIN, PTPN14, and TMSB4X in
DLBCL relapse.
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SHARPIN
SHARPIN was reported as a novel member of the linear ubiquitin chain assembly complex
(LUBAC) complex (Ikeda et al. 2011, Tokunaga et al. 2011). Besides, LUBAC also consists of the
catalytic HOIP subunit and accessory subunits, HOIL-1L. SHARPIN protein consists of an NZF
domain, which is the ubiquitin-binding domain and responsible for linking SHARPIN to other
LUBAC complex components. The LUBAC complex binds to IKKr (also known as NEMO) in the
IKK complex and assembles linear polyubiquitin chains on IKKr, thus activates NEMO.
Overexpression of LUBAC or its members may be involved in tumorigenesis through activation of
the anti-apoptotic function of NF-κB. For example, SHARPIN was shown to promote
hepatocellular carcinoma progression. Also, CYLD, A20, OTULIN, are recruited to the LUBAC
and cooperate to limit gene activation.
As mentioned, in our cohort SHARPIN mutations were predominantly discovered in the
non-GCB subtype (4 out of 5 cases). The mutation p.S282T (C144099354G) was particularly
interesting because it was in the NZF domain (Figure 4.3 A). What is more, it was recurrent in 2
out of 5 cases. Its VAFs were stable or increased after treatment (0% to 44%, 60% to 52%).
Meanwhile, the Polyphen2_HDIV (Adzhubei et al. 2010, Adzhubei, Jordan and Sunyaev 2013)
prediction suggested this mutation was “deleterious”.
PTPN14
PTPN14 was found to be mutated in 17% of all cases, among the top mutated genes of the
NF-κB pathway. Interestingly, all the mutations were in the non-GCB subgroup, accounting for
27% of all non-GCB cases. It suggests PTPN14 mutations are correlated to non-GCB subtype.
Consistently, recent studies in DLBCL showed PTPN14 promotes the degradation of mRNA decay
factor roquin2 in a KLHL6 dependent method and thus inhibits the NF-κB pathway. Therefore,
loss-of-function PTPN14 mutations possibly promote DLBCL relapse.
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PTPN14 is a member of the protein tyrosine phosphatases (PTPs) superfamily, which
contains receptor and non-receptor PTPs. PTPN14 is a non-receptor PTP, which consists of a
FERM domain, a PTP domain, and Linker 1, 2, and 3 (Figure 4.3B). The functions of each domain
are unclear yet. Recent evidence suggests PTPN14 specifically interacts with Rouqin2 through its
PTP domain (Choi et al. 2018b, Choi et al. 2018a, Choi, Zhou and Busino 2019). Studies also
showed PTPN14 can recruit YAP1 through Linker 2 and regulate the YAP1 function (Liu et al.
2013, Wilson et al. 2014). The positions of PTPN14 mutations identified in our data are labeled in
Figure 4.3B. Most of these mutations were predicted to be damaging or deleterious, especially the
R298X, a stopgain mutation leading to the loss or truncation of PTPN14 protein. Consistently, the
PTPN14 mRNA level was lower in the relapsed/refractory DLBCL cases (sensitive/relapsed = 2fold, p = 0.019). These results imply the majority of these PTPN14 mutations were loss-offunction, which played an important role in the DLBCL relapse by activation of the NF-κB
pathway.
TMSB4X
TMSB4X mutations were identified only in our non-GCB subtype. The mutation frequency
was 0% in diagnostic samples and 13.33% in relapsed/refractory non-GCB samples. The most
interesting fact was that TMSB4X mutations were detected in two case pairs and both displayed a
significant enhance regarding mutation VAF (from 0 to 0.2; from 0 to 0.79). As mentioned, it was
also one of the genes with top evolution.
TMSB4X encodes protein thymosin β4, the major G-actin-sequestering molecule in cells.
In cells, there are two types of actin, the F-actin, which is also known as the actin filament, and the
G-actin, which is also known as the actin subunit. There is a dynamic balance between these two
types. When thymosin β4 sequesters the G actin, the growth of the F actin is inhibited. Thus, the
main function of thymosin β4 is to regulate the process of actin polymerization. Meanwhile, it also
plays an important role in promoting cell migration, angiogenesis, and cell survival (Crockford et
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al. 2010) (Figure 4.3C). Moreover, it was demonstrated to block RelA/p65 nuclear translocation,
therefore repressing the NF-κB pathway. Recently, TMSB4X mutations were identified in DLBCL
and described as a target of aberrant SHM (Qiu et al. 2011, Khodabakhshi et al. 2012). Meriranta,
L. et al reported TMSB4X impacted the DLBCL patient’s overall survival (Meriranta et al. 2017).
A previous study revealed thymosin β4 protein level was increased in BCR inhibitor-treated
DLBCL xenografts, in which ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, and idelalisib,
a specific Phosphatidylinositol-4,5-bisphosphate 3-kinase delta (PI3Kδ) inhibitor were applied
(Jacobs et al. 2017). This finding in the context of the BCR function is unclear.
In summary, TMSB4X is potentially involved in the inhibition of BCR and the NF-κB
pathway, and loss of TMSB4X may contribute to the DLBCL relapse, but the underlying
mechanisms are elusive. The association between TMSB4X mutation evolution and DLBCL relapse
has never been reported.
Conclusion
In our cohort, NF-κB pathway mutations presented in most of the cases and evolved from
diagnosis (70%) to relapse (78%). Interestingly, only the canonical mutations were identified.
Several potential novel targets were discovered to cooperate in the regulation of NF-κB pathway
(Figure 4.3D): SHARPIN induces the NF-κB pathway activation through conjugation of linear
polyubiquitin chains to IKKγ; PTPN14 inhibits the NF-κB pathway by promoting the degradation
of Roquin2, which represses the NF-κB inhibitor A20; TMSB4X inhibits the NF-κB pathway
through blocking the RelA/p65 nuclear translocation.
As expected, they were all more correlated with the non-GCB subtype. The mechanisms
are not well understood. Further population based as well as functional studies could shed more
light on their roles in the pathogenesis and relapse of DLBCL.
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Figures
Figure 4.1 The canonical and noncanonical NF-κB pathway
The canonical NF-κB pathway is triggered by signals from immune receptors, which activate the
kinase TAK1, then further activate IKKb, phosphorylating IκBα, or p105. Upon phosphorylation
by IKK, IκBα and p105 are targeted for ubiquitin-dependent degradation, resulting in the nuclear
translocation of canonical NF-κB family members, in the form of various dimeric complexes
including RELA–p50, c-REL–p50, and p50–p50. By contrast, the non-canonical NF-κB pathway
selectively responds to a subset of TNFR superfamily members and causes the activation of NIK.
NIK phosphorylates and activates IKKα, which in turn phosphorylates p100, leading to the nuclear
translocation of p52 and RELB (Sun 2017).
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Figure 4.2 The NF-κB pathway was revealed to be significantly more enriched in the
relapsed/refractory cohort by the DAVID Gene Functional Classification
(A) Top significant pathways with smallest p values identified by the DAVID Gene Functional
Classification in the diagnostic and relapsed/refractory samples. Eleven, twenty-one, and sixteen
pathways were defined as significant pathways in the diagnostic samples only, the
relapsed/refractory samples only, and both the diagnostic and the relapsed/refractory samples,
respectively. The NF-κB activation was discovered to be a significant pathway only in the
relapsed/refractory samples.
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(B) The NF-κB activation was significantly more enriched in the relapsed/refractory samples
compared to the diagnostic samples. * denotes p value less than 0.05.
Term

Sample

99.NF-κB_activation

Diagnostic
Relapsed/refractory
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Fold
Enrichment
1.72
2.32

p value
0.248
*0.034

Figure 4.3 SHARPIN, PTPN14, and TMSB4X cooperate in the regulation of NF-κB
pathway
(A) SHARPIN protein structure. Red lines indicate the positions of mutation p.S282T
(C144099354G).

(B) PTPN14 protein structure. Red lines indicate the positions of mutations identified in our cohort.

(C) Thymosin β4 protein functions and the possible mechanisms of thymosin β4 in DLBCL relapse.
thymosin β4 can inhibit the NF-κB pathway by blocking RelA/P65 nuclear translocation. Thus, the
loss of TMSB4X possibly activates the NF-κB pathway.
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(D) SHARPIN, PTPN14, and TMSB4X cooperate in the regulation of NF-κB pathway.
SHARPIN, as a member of LUBAC complex, activates the NF-κB pathway by ubiquitinating the
IKKγ. PTPN14 inhibits the NF-κB pathway by increasing the KLHL6-dependent Roquin 2
degradation, thus promoting the NF-κB pathway negative regulator A20. TMSB4X represses the
NF-κB pathway by blocking the NF-κB nuclear translocation. Notably, mutations of SHARPIN,
PTPN14, and TMSB4X were predominantly discovered in the non-GCB subtype, which is
consistent with their critical roles in the NF-κB pathway regulation.
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Chapter 5: A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma
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Background
MYC rearrangement is one of the common cytogenetic abnormalities in aggressive B-cell
lymphoma, including MYC-immunoglobulin (-IG) and -non-immunoglobulin (-non-IG)
rearrangements. In DLBCL, MYC rearrangements were identified in about 12% of the cases, and
approximately half of these aberrations involve the non-IG partners (Chong et al. 2018). However,
the MYC-non-IG rearrangements were barely described in detail, due to the large variety of the
non-IG partners and lack of specific study to investigate their significance in the disease
development. Herein, we present a case with the rearrangement between MYC and AICDA,
resulting in MYC overexpression. To our knowledge, this is the first report of a DLBCL case with
AICDA-MYC rearrangement. Strikingly, the fusion clone substantially expanded during treatment,
which gave us a clue of the possible dynamic genome landscape change over time in this refractory
DLBCL case.
Results
The patient was a 57-yr-old female presented with diffuse lymphadenopathy and
splenomegaly. The right axilla lymph node was biopsied, and the pathology showed an EBVinduced lymphoproliferative disorder and focal DLBCL (non-GCB subtype). Conventional
cytogenetics identified the presence of two abnormal clones, one pseudodiploid clone and one
hyperdiploid clone (Supplemental Figure 1A, B). Her bone marrow biopsy exhibited involvement
by lymphoma. The bone marrow conventional cytogenetics was normal female karyotype (46, XX
[20]) and concurrent FISH studies were negative for abnormalities of loci associated with CLL,
NHL, and marginal zone lymphoma. Clinically, the patient had an IPI score at 3 and Ann Arbor
stage IVB. After six cycles of R-CHOP therapy, the patient showed poor response with the PETCT scan indicating the persistence of disease. The left axilla lymph node was re-biopsied and
showed a persistence of DLBCL. Conventional cytogenetic studies revealed the presence of a
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hypotetraploid stemline and its sideline (Supplemental Figure 1C, D). The bone marrow biopsy
resulted in the same cytogenetics and FISH profile with the first bone marrow biopsy. The patient
was later enrolled in a prospective phase III clinical trial using STAT3 inhibitor Ruxolitinib, to
which a poor response was shown, and the patient died after 11 doses (10 mg, BID).
Retrospectively, we performed RNA-seq to probe the potential genomic alterations that
may contribute to the treatment resistance, by which an AICDA and MYC fusion was identified in
the resistant biopsy sample. This in-frame fusion started at the AICDA intron 1 and followed by
MYC exon 2 (Figure 1). To confirm this gene fusion, real-time PCR (RT-PCR) using specific
primers was performed on both the diagnostic and resistant biopsy samples. Notably, the resistant
sample showed a much stronger signal than the diagnostic sample while Sanger sequencing of the
PCR product confirmed the fusion sequence (Figure 1). These results suggest that this
rearrangement was de novo and the affected cells evolved from a minor into a major clone upon RCHOP treatment. The presence of AICDA promoter and exon 1 were also verified by RT-PCR
(Supplementary Figure 2).
To better illustrate the clonal evolution as well as facilitate a large-scale screening, we
designed an AICDA dual-color break-apart probe and a MYC/AICDA-dual-fusion probe and
performed the FISH study on the FFPE tissue sections of both diagnostic and resistant samples. We
first examined the MYC locus using the conventional MYC break-apart probe which showed an
MYC rearrangement in the resistant sample (Figure 2B), but not in the diagnostic sample (Figure
2A). Next, we examined the AICDA and MYC rearrangement using the two self-designed probes
and found that both probes showed positive results in the resistant sample but not in the diagnostic
sample (Figure 2A, B). The findings were consistent with the RT-PCR result, suggesting a clone
evolution occurred during the immuno-chemotherapy administration. It is worth noting that RTPCR has a higher sensitivity than FISH, and thus, a very small number of the fusion clone might
be detected by RT-PCR in the diagnostic sample but not by FISH (Wu et al. 2013).
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Because this rearrangement positioned MYC to the downstream of the AICDA promoter, which is
highly active in germinal center B cell, we speculate that it may result in MYC overexpression. To
prove that, immunohistochemistry (IHC) staining was performed in both diagnostic and resistant
samples. As expected, the percentage of MYC positive cells in the resistant sample (positive/total
= 50.320%) was substantially higher than that in the diagnostic specimen (positive/total =4.438%)
(Figure 2C). Moreover, a significant increase of Ki-67 positive cells was also observed in the
resistant sample compared with the diagnostic sample (40% to 70%), which is consistent with the
aggressive behavior of lymphoma cells upon MYC overexpression.
Next, we sought to address another important question that whether this rearrangement is
a recurrent event in DLBCL. To this end, we performed the FISH screening in a cohort of DLBCL
cases consisting of 164 de novo and 9 resistant/refractory DLBCL samples. The FISH analysis was
successfully achieved in 136 out of 173 samples (78.6%). However, none of these cases exhibited
an AICDA-MYC fusion. Nevertheless, besides the original case, MYC and AICDA rearrangements
were identified in five and two cases, respectively, with one case concurrently carrying both
rearrangements. Additionally, MYC abnormality or copy number aberrations were identified in 50
cases. However, the two cases exhibiting AICDA translocation had unknown destinations. This data
suggests that the AICDA-MYC fusion is likely a rare and maybe isolated event, which further
manifests the high diversity of MYC-non-IG rearrangement in DLBCL.
Discussion
The clinical outcome of patients with DLBCL has been significantly improved in the
immune-chemotherapy era. However, approximately half of patients are relapsed or refractory to
the therapy, and eventually, succumb to the disease. Thus, there has been an increasing interest in
genomic mechanisms of refractory/relapsed DLBCL. MYC is one of the most notorious oncogenes
in haematological malignancies. MYC not only directly promotes cell proliferation, but also
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protects cancer cells from DNA damage, thereby allowing them to survive longer (Kumari, Folk
and Sakamuro 2017). MYC overexpression is found to be closely associated with chemo-resistance
in various types of lymphomas, including DLBCL, mantel cell lymphoma, T-cell lymphoma, and
Burkitt lymphoma. In DLBCL, MYC serves as an independent biomarker for prognosis prediction,
on both genetic and protein expression levels (Thieblemont and Brière 2013). Of note, a previous
study has demonstrated that only MYC-IG, but not MYC-non-IG, rearrangement is a prognostic
marker for shorter survival in DLBCL patients (Copie-Bergman et al. 2015). This is likely because
MYC-non-IG rearrangement is highly versatile and was barely studied specifically, especially in
association with the MYC expression level. Our previous study has shown that the genetic alteration
of MYC is not well correlated with the protein level (Ren et al. 2018), which further highlights the
necessity of multi-dimensional investigations in specific cases. This case presented herein exhibited
a remarkable selection of the AICDA-MYC fusion clone between the diagnostic and resistant
tumors. Accordingly, the percentage of MYC positive cells was increased, indicating that this
AICDA-MYC fusion which positioned MYC downstream of the AICDA promoter led to MYC
overexpression. Notably, this patient had an extraordinarily short progression-free survival (0.25
yr) and overall survival (0.92 yr). Although it is hard to establish the significance of AICDA-MYC
fusion in a single case, the clone selection, at least, suggests that it is a potential mechanism
mediating R-CHOP resistance and might be a valuable biomarker in the DLBCL prognosis.
Previous research has established that MYC needs a second-hit mutation in tumorigenesis.
For example, MYC as a hallmark in Burkitt lymphoma promotes the proliferation of cells. However,
increased proliferation introduces many mutations making cells decease easily (Kumari et al.
2017). The BCL2 rearrangement or MCL1 mutation as a second hit enhances cell survival and
facilitates tumorigenesis (Rosenthal and Younes 2017). Interestingly, AICDA, with restricted
expression in the germinal center stage, plays an essential role in immunoglobulin gene class switch
recombination and somatic hypermutation of B cells (Zan and Casali 2013). AICDA was also
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reported to promote double-strand breaks, and therefore introduce gene translocations (So and
Martin 2019, Takizawa et al. 2008). In DLBCL, AICDA was found to be highly active in the nonGCB subtype and to be a potential contributing factor to both the inferior outcome and greater
epigenetic heterogeneity of this subtype (Lossos, Levy and Alizadeh 2004, Teater et al. 2018).
However, the genetic aberration of AICDA has not been reported yet. In our FISH screening, we
identified two cases with AICDA rearrangement besides the AICDA-MYC fusion case, which
suggest that the AICDA genetic alteration is not an accidental event in DLBCL and may relate to
the activation of AICDA in germinal center B cells. The simultaneous expression of MYC with
AICDA may cause alterations in guardian genes, such as those in DNA repair, thus help the tumor
surpass the check point and promote lymphoma cell proliferation like a second-hit mutation.
Potentially, the high level of both AICDA and MYC facilitated the accumulation of more resistant
mutations and increased the aggressive index of the clone.
As a summary, we, for the first time, reported an AICDA-MYC translocation in a DLBCL
case, which potentially led to immunochemotherapy resistance. Although this fusion was not
recurrently detected in a large cohort of DLBCL cases, the results presented in the current study
suggest that MYC-non-IG rearrangement in DLBCL is worthy of further investigation, especially
in the setting of refractory and relapse mechanisms.
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Figures
Figure 5.1. Schematic diagram of the AICDA and MYC locations and fusions verified by
RT-PCR and Sanger sequencing
This in-frame fusion started at the AICDA intron 1 (AICDA, chr12, breakpoint 8761704), which
was followed by MYC exon 2 and 3 (MYC, chr8, breakpoint 128750496). Diag. stands for the
diagnostic sample and Resist. stands for the resistant sample. GAPDH was used as a control and
fusion stands for the AICDA-MYC fusion gene detected by the AICDA-MYC-rearrangementspecific primers.
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immunohistochemistry results on MYC and Ki67
Representative fluorescence in situ hybridization (FISH) images from (A) the diagnostic right
axillary lymph node and (B) the resistant left axillary lymph node samples. The diagnostic sample
illustrates negative results for MYC (8q24) rearrangement with a break-apart probe (two normally
juxtaposed red and green signals), AICDA (12p13.31) rearrangement with a break-apart probe (two
normally juxtaposed red and green signals), and AICDA-MYC fusion with the dual fusion probes
(two independent red and green signals each), while the follow-up sample illustrates abnormalities
of the FISH probes targeting the same loci (separation of the red and green signals with both the
MYC and AICDA break apart probes and overlap of the red and green signals with the AICDAMYC dual fusion probe, red arrow). MYC and Ki67 protein levels in diagnostic and resistant
samples were detected by immunohistochemistry (C). The MYC protein level in the resistant
sample (positive/total = 1336/2655, 50.320%) was significantly higher than the diagnostic sample
(positive/total = 122/2749, 4.438%). Ki-67 positive cells were significantly increased in the
resistant sample compared with the diagnostic sample (40% to 70%). To address whether this
rearrangement is a recurrent event in DLBCL, the FISH assay was successfully conducted in 136
out of 173 samples (78.6%), among which 60 cases were negative for abnormalities of 8q24 and/or
12p13.31/12, five cases exhibited rearrangement of the MYC locus, two cases exhibited AICDA
translocation, with one case concurrently carrying both rearrangements. Additionally, MYC
abnormality or copy number aberrations were identified in 50 cases (D). Diag. stands for the
diagnostic sample and Resist. stands for the resistant sample.
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(A) Representative fluorescence in situ hybridization (FISH) images from the diagnostic right
axillary lymph node samples

(B) Representative fluorescence in situ hybridization (FISH) images from the resistant left
axillary lymph node

(C) MYC and Ki67 protein levels in diagnostic and resistant samples were detected by
immunohistochemistry
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(D) FISH screening in the TMA samples
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Figure 5.3. Representative karyotypes from conventional cytogenetics studies (G-banding
using Wright’s stain according to standard protocols)
The nomenclature was written according to guidelines at the time of testing (International System
for Human Cytogenetic Nomenclature (ISCN) 2009). Arrows show structural changes.
(A) The first clone from the diagnostic right axillary lymph node
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(B) The second clone from the diagnostic right axillary lymph node
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(C) The primary clone from the follow-up left axillary lymph node
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(D) The second clone from the follow-up left axillary lymph node
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Figure 5.4 The integrities of AICDA promoter and exon 1 were verified by RT-PCR in the
resistant sample
The RT-PCR products were confirmed by Sanger sequencing. M stands for the markers, p1 stands
for the primer pair 1 and p2 stands for the primer pair 2. The forward primers were in the AICDA
promoter or exon 1 and reverse primers were in the MYC exon 2.
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Chapter 6: Major conclusions and future direction
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Major conclusions
The resistance to immunotherapy has largely limited the survival of DLBCL patients.
However, the nature and mechanisms of the treatment resistance remain unclear. This dissertation
mainly describes the evolution patterns and mutation events identified by WES in
relapsed/refractory DLBCL. Our study generates fresh insight into the genomic landscape and
mutation dynamics in paired diagnostic and relapsed/refractory DLBCL samples.
In Chapter 2, we described the overall mutation landscape in our paired initial and
relapsed/refractory DLBCL samples. Patients with the GCB subgroup experienced longer relapsefree-survival than the non-GCB cases (5.32 yr vs. 1.57 yr, p = 0.016). The most frequent gene
mutations were in the classic pathogenic pathways. Particularly NF-ΚB pathway mutations, such
as MYD88 mutations, were significantly more enriched in the initial biopsies of our cohort than the
whole de novo DLBCL population, suggesting MYD88 mutated cases are prone to be relapsed or
refractory. Consistently, when classifying our cases according to the newly developed method
based on genomic abnormalities, the MCD subgroup, whose hallmarks include MYD88 mutations,
was significantly more enriched in our diagnostic samples than the whole de novo DLBCL
population.
In Chapter 3, we investigated the evolution of our diagnostic and relapsed/refractory
DLBCL samples. First, we found the top evolved in our total samples were BCL6, PIM1, and
TMSB4X. In the non-GCB subgroup, TMSB4X exhibited the most evolution of mutation frequency,
whereas, in the GCB subgroup, B2M had the top evolution of mutation frequency. Mainly two
evolution patterns were discovered: Pattern 1 had diagnostic and relapsed/refractory mutations
mostly overlapped, indicating the initial mutations were resistant and survived chemotherapy;
Pattern 2 had a considerable part of novel mutations which were only present in the
relapsed/refractory samples, indicating these mutations induced under treatment stress.
Interestingly, Pattern 2 is correlated to a worse prognosis. The patients with Pattern 2 were younger
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at diagnosis and relapse, possibly correlating with the non-GCB subtype (p = 0.05, marginal), and
had relatively lower SNV numbers. What is more, they exhibited a shorter relapse-free-survival.
The median time before relapse in the non-GCB cases with Pattern 2 was extremely short (median
0.78 yr, range 0.3-3.5 yr).
Finally, we addressed the critical role of the NF-ΚB pathway mutations in the relapse of
DLBCL. The NF-ΚB pathway mutations were dominant in both diagnostic and relapsed/refractory
samples (70% vs 78%). The mutation frequency increased from 67% to 80% in the non-GCB
subtype. Moreover, all the mutations were in the canonical pathway. Three novel potential genes
for further studies were emphasized, including SHARPIN, PTPN14, and TMSB4X.
Additionally, we reported a novel AICDA-MYC translocation in a DLBCL case, which
potentially led to immunochemotherapy resistance, suggesting that MYC-non-IG rearrangement in
DLBCL is worthy of further investigation, especially in the setting of refractory and relapse
mechanisms.
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Future directions
Validation in larger cohorts are needed
To our knowledge, our study is the largest cohort with paired diagnostic and
relapsed/refractory DLBCL samples. However, these results should be interpreted with caution. To
validate the findings, larger cohorts are needed to lower the bias from sampling.
Are patients with MYD88 mutations or MCD subgroup prone to relapse?
MYD88 mutations, particularly L265P, were reported as a possible unfavorable prognostic
marker. However, the correlation between MYD88 mutations and DLBCL relapse has never been
studied. In our study, MYD88 mutations were significantly more enriched than the overall de novo
DLBCL population, suggesting patients with MYD88 mutations are prone to be relapsed or
refractory. Yet, validation in larger cohorts is needed. Besides, direct evidence is needed, such as
controlled functional studies comparing the differences of immunotherapy resistance between wildtype and mutated MYD88 in DLBCL cell lines, and population-based studies comparing the relapse
possibilities in de novo DLBCL with or without MYD88 mutations.
The newly developed classification based the genomic abnormalities in DLBCL has been
attracting a lot of interest. It uncovers therapeutic vulnerabilities based on tumor genetics and
provides a potential nosology for precision-medicine strategies in DLBCL. However, so far, this
classification has only focused on de novo DLBCL. There have been no studies in
relapsed/refractory DLBCL. We applied this novel system in our relapsed/refractory DLBCL pool
and found the MCD subtype was significantly enriched, suggesting the MCD subgroup is prone to
relapse. Similarly to MYD88 mutations, larger cohorts are needed for validation purpose and direct
evidence are necessary from population-based controlled studies.
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What prognostic values do mutation patterns have?
One of the most significant current discussions in DLBCL relapse lies in the evolution
patterns from diagnosis to relapse. In our study, we identified two major evolution patterns. What
is more, our data suggested cases with considerable novel mutations induced by
immunochemotherapy at relapse have worse prognoses. With further validation in larger sized
cohorts with paired diagnostic and relapsed/refractory samples, this finding could help predict
survival in relapsed/refractory DLBCL.
Novel genes for future studies
In our study, three potential novel targets were discovered in the NF-κB pathway, including
SHARPIN, PTPN14, and TMSB4X.
To validate our findings, population-based studies are needed to compare the mutation
status in relapsed/refractory vs. sensitive DLBCL patients. To further study the role of SHARPIN
in DLBCL relapse, the resistance to therapy need to be compared in DLBCL cell lines with wildtype or mutant SHARPIN. SHARPIN, as a member of the LUBAC complex, interacts with the other
two components HOIP and HOIL-1. Immunoprecipitation will be conducted to monitor the
interaction between SHARPIIN and HOIP or HOIL-1 in cell lines with wild-type or mutant
SHARPIN. Furthermore, the function of LUBAC will be tested by studying the polyubiquitin level
of IKKγ. The NF-κB activation level will be investigated to dissect the mechanism of SHARPIN.
Besides validation in larger cohorts, direct evidence including functional studies
comparing the resistance of DLBCL cell lines with wild-type PTPN14 and mutated PTPN14 is
needed. The PTPN14 mutations are most possibly loss-of-function. Interests could be focused on
the catalytic PTP domain mutations, which were reported to interact with Roquin 2 and regulate
the activation of the NF-κB pathway in a KLHL6-dependent manner. Thus, the protein level of
Roquin2 and the activation of the NF-κB pathway would be monitored in both cell lines with wild-
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type or mutated PTPN14. Besides, studies showed PTPN14 can recruit YAP1 through linker2 and
regulate the YAP1 function. This implied that PTPN14 may recruit and regulate multiple partners.
To identify the other PTPN14 partners, proteomics could be conducted in the DLBCL cell lines
with wild-type or mutant PTPN14 knocked-in constructs.
Very little is known about the functions and mechanisms of TMSB4X except for actin
polymerization. We revealed its high mutation frequency in DLBCL and possible role in predicting
prognosis and determining drug sensitivity in DLBCL, which may act through inhibition of the NFκB pathway. However, these are very primary clues and future studies are needed to demonstrate
this hypothesis.
We reported a novel fusion between MYC and AICDA, potentially leading to the
overexpression and high proliferation in a refractory DLBCL. In our FISH screening, we did not
identify another AICDA-MYC fusion out of 176 samples, suggesting this fusion is a rare event.
Thus, population-based studies might not yield significant findings. However, our study suggests
MYC-non-IG fusion is a potential mechanism mediating R-CHOP resistance and might be a
valuable examination candidate in the DLBCL diagnosis, which needs to be confirmed by larger
population studies, in which the MYC-non-IG fusion partners need to be stratified. The function of
AICDA-MYC fusion needs to be validated by functional studies.
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Chapter 7: Materials and methods
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Clinical specimen collection
Human tissues were collected or transferred under IRB-283-11 and IRB 161-95-FB with
patients’ consent, approved by the University of Nebraska Medical Center (UNMC) Institutional
Review Board.
Dataset download
WES data of paired diagnostic and relapsed/refractory samples were downloaded from the
study

SRP039525

on

the

SRA

platform

(https://www.ncbi.nlm.nih.gov/sra?linkname=bioproject_sra_all&from_uid=240335). WES data
of 30 relapsed DLBCL samples were kindly shared by Morin, RD., et al.
DNA and RNA isolation
Extraction and purification of DNA and RNA from tumor cases were performed using
AllPrep DNA/RNA Mini Kit (Qiagen Inc., Valencia, CA) or ALLPrep DNA/RNA FFPE Kit
(Qiagen Inc). Germline DNA was isolated from patient peripheral blood using DNeasy Blood and
Tissue Kit (Qiagen Inc.).
WES and data analyses
WES was performed on our paired diagnostic and relapsed/refractory DLBCL samples as
well as the matched germline. Briefly, after DNA quality control, 150-bp paired-end libraries were
prepared with the TrueSeq RNA preparation kit (Illumina Inc., San Diego, CA), and highthroughput sequencing was performed at the University of California, Los Angeles (UCLA)
Technology Center for Genomics and Bioinformatics, using Roche NimbleGen SeqCap EZ
Human Exome Kit v3.0 on HiSeqX Sequencing systems. FASTQC reports were evaluated for
each sample to evaluate the quality of basic statistics.
Raw sequencing reads were mapped to the human reference genome GRCh38 using BWA.
Local realignment and base quality recalibration were performed using GATK. VarScan called
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variants for paired diagnostic and relapsed/refractory DLBCL and their matched germline samples.
Then variants were filtered to remove variants only identified or common ( > 1%) in the matched
germline, synonymous SNV, variants with extremely low VAF ( < 5%), or without adequate
supporting reads (have no reads in forward or reverse or both strands). Extra filters were applied to
remove variants on the in-house common false-positive variants lists. Only genes expressed in B
cells were kept, based on the in-house RNA-seq and GEP data. The same filters were applied to
the 30 downloaded relapsed samples as well.
Mutation patterns identification based on Venn diagrams
The Venn diagrams were generated based on the presence of each mutation in the sample
pairs using the Meta Chart online platform (https://www.meta-chart.com/). The two patterns were
manually decided based on the Venn diagrams, particularly the ratios of shared to
relapsed/refractory variants. A scatter plot was generated (Figure 7.1), whose x axis was the ratio
of shared to diagnostic variants, whereas the y axis was the ratio of shared to relapsed/refractory
variants. Consistently, all cases were automatically clustered into two separate groups in the scatter
plot. The ratio of shared to relapsed/refractory variants was 0.87±0.04 in Pattern 1, whereas that in
Pattern 2 was 0.44±0.15. Thus, the cut-off of the ratio of shared to relapsed/refractory variants was
defined as 70%.
RNA-seq and candidate gene fusion identification
Qualified libraries were sequenced on an Illumina HiSeq 2000 platform. Hg19 RefSeq
(RNA sequences, GRCh37) was employed for reads mapping. Fusioncatcher (Fusioncatcher-1.00)
(Nicorici et al. 2014) and TopHat-Fusion (TopHatFusion-0.1.0) (Kim and Salzberg 2011) were
applied to detect gene fusion based on the paired-end reads in different samples.
PCR validation
GAPDH was used as the inner control gene. PCR primers used in this study are as follows:
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GAPDH

forward:

GACAGGCAACTTGGCAAATC;

GAPDH

reverse:

CCTTCTCTAAGTCCCTCCTACA; fusion gene forward: GACAGCACTAGCTCCACAAA;
fusion gene reverse: CTCCTCGTCGCAGTAGAAATAC;
Immunohistochemistry staining
Tissues from DLBCL cases were obtained from the University of Nebraska Medical
Center, embedded in paraffin. Slides were deparaffinized in xylene and rehydrated through graded
ethanol. Endogenous peroxidase was blocked using peroxidase quenching solution for 10 min. The
slides were then boiled in citrate buffer (pH 6.0) for 1 hour, allowed to cool and rinsed with PBS.
The sections were stained overnight at 4 °C with primary antibody against MYC (1:50, ab32072
from Abcam, Cambridge, MA) and Ki67 (1:100, MIB-1, Dako, Carpinteria, CA, USA). Slides were
then washed with PBS and incubated with HRP polymer conjugate for 1 h at room temperature,
followed by PBS wash and then stained with DAB reagent. Photographs were taken using Roche
Ventana Scan HT.
Fluorescence in situ hybridization (FISH)
To confirm the AICDA-MYC fusion, FISH studies were performed at the Human Genetics
Laboratory per their established protocols. The AICDA and MYC regions were assessed using the
Vysis LSI MYC dual-color break-apart-rearrangement probe (Abbott Molecular, Des Plaines, IL),
a custom AICDA dual-color break-apart probe combined with a copy control probe for chromosome
12 (Biocare Medical, Pacheco, CA) and a MYC/AICDA dual fusion probe which spans the MYC
locus and BAC clones (Empire Genomics) that span the AICDA locus (RP11-681B8/RP11164J16).
Statistical analyses
Continuous variables were compared with the Wilcoxon rank-sum test or two-tailed
Student’s t-test. Mutation frequencies of genes between our cohort and reported were compared
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using the chi-square test or Fisher’s exact test. All tests were two-sided, unless otherwise specified,
and significance was set at p < 0.05. Statistical analyses were performed with R-language statistical
packages. Significant differences among groups were considered at p values below 0.05 (*). p
values below 0.01, 0.001 and 0.0001 were denoted as **, *** and ****.
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Figures
Figure 7.1. Shared SNV percentage at diagnosis and relapse in two patterns.
The ratio of shared to relapsed/refractory variants was 0.87±0.04 in Pattern 1, whereas that in
Pattern 2 was 0.44±0.15. Thus, the cut-off of the ratio of shared to relapsed/refractory variants was
defined as 70% manually (indicated by the red dash line).
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